UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q



(Mark One)
x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended ~~June 30, 2017~~March 31, 2018
or
o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to

Commission File Number 001-36841

INOVALON HOLDINGS, INC.

(Exact name of registrant as specified in its charter)



Delaware (State or other jurisdiction of incorporation or organization)	47-1830316 (I.R.S. Employer Identification No.)
4321 Collington Road, Bowie, Maryland (Address of principal executive offices)	20716 (Zip Code)

(301) 809-4000

~~Registrant's~~Registrant’s telephone number, including area code

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of ~~"large~~“large accelerated filer,~~" "accelerated filer"~~” “accelerated filer,” “smaller reporting company” and ~~"smaller reporting company" and "emerging~~“emerging growth ~~company"~~company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer x	Accelerated filer o	Non-accelerated filer o (Do not check if a smaller reporting company)	Smaller reporting company o Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of ~~July 28, 2017,~~April 30, 2018, the registrant had ~~63,313,515~~71,660,149 shares of Class A common stock outstanding and ~~82,498,213~~80,608,685 shares of Class B common stock outstanding.

~~Table of Contents~~

INOVALON HOLDINGS, INC.

FORM 10-Q

FOR THE THREE ~~AND SIX~~ MONTHS ENDED ~~JUNE 30, 2017~~MARCH 31, 2018

TABLE OF CONTENTS



		Page
PART I—FINANCIAL INFORMATION
Item 1.	Condensed Consolidated Financial Statements (unaudited)	1
	Condensed Consolidated Balance Sheets as of ~~June 30, 2017~~March 31, 2018 and December 31, ~~2016~~2017	1
	Condensed Consolidated Statements of ~~Income~~Operations for the three ~~and six~~ months ended ~~June 30,~~March 31, 2018 and 2017 ~~and 2016~~	2
	Condensed Consolidated Statements of Comprehensive (Loss) Income for the three ~~and six~~ months ended ~~June 30,~~March 31, 2018 and 2017 ~~and 2016~~	3
	Condensed Consolidated Statements of Cash Flows for the ~~six~~three months ended ~~June 30,~~March 31, 2018 and 2017 ~~and 2016~~	4
	Notes to Condensed Consolidated Financial Statements	5
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	13
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	23
Item 4.	Controls and Procedures	24

PART II—OTHER INFORMATION
Item 1.	Legal Proceedings	25
Item 1A.	Risk Factors	25
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	25
Item 3.	Defaults Upon Senior Securities	26
Item 4.	Mine Safety Disclosures	26
Item 5.	Other Information	26
Item 6.	Exhibits	27

SIGNATURES		28

~~Table of Contents~~

PART I—FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements

INOVALON HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited, in thousands, except share and par value amounts)


	June 30, 2017			December 31, 2016
	(Unaudited)						March 31, 2018			December 31, 2017
ASSETS
Current assets:
Cash and cash equivalents	$	192,012		$	127,683		$	410,000		$	208,944
Short-term investments	339,536			445,315			40,275			267,288
Accounts receivable (net of allowances of $5,817 and $5,865 at June 30, 2017 and December 31, 2016, respectively)	95,698			85,591
Accounts receivable (net of allowances of $1,545 and $2,038 at March 31, 2018 and December 31, 2017, respectively)							78,401			90,054
Prepaid expenses and other current assets	10,851			12,100			14,200			10,441
Income tax receivable	7,837			15,165			11,810			11,987
Total current assets	645,934			685,854			554,686			588,714
Non-current assets:
Property, equipment and capitalized software, net	86,898			76,420			139,989			125,768
Goodwill	185,559			184,557			184,932			184,932
Intangible assets, net	96,027			103,549			85,475			89,326
Other assets	5,277			2,964			10,474			6,338
Total assets	$	1,019,695		$	1,053,344		$	975,556		$	995,078
LIABILITIES AND STOCKHOLDERS' EQUITY
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	26,134		$	16,474		$	32,010		$	34,109
Accrued compensation	14,052			15,211			12,927			18,592
Other current liabilities	8,973			9,468			19,163			15,277
Deferred revenue	11,860			11,850			12,068			6,954
Deferred rent	1,118			1,016			805			1,818
Credit facilities	37,500			30,000			45,000			45,000
Capital lease obligation	117			115			1,815			336
Total current liabilities	99,754			84,134			123,788			122,086
Non-current liabilities:
Credit facilities, less current portion	213,750			236,250			180,000			191,250
Capital lease obligation, less current portion	155			215			15,134			12,109
Deferred rent	911			1,457			1,567			219
Other liabilities	15,007			13,158			2,111			—
Deferred income taxes	32,312			34,553			21,195			26,642
Total liabilities	361,889			369,767			343,795			352,306
Commitments and contingencies (Note 5)
Stockholders' equity:
Common stock, $0.000005 par value, 900,000,000 shares authorized, zero shares issued and outstanding at each of June 30, 2017 and December 31, 2016, respectively	—			—
Class A common stock, $0.000005 par value, 750,000,000 shares authorized; 75,164,389 shares issued and 63,958,397 shares outstanding at June 30, 2017; 72,271,298 shares issued and 64,786,705 shares outstanding at December 31, 2016	—			—
Class B common stock, $0.000005 par value, 150,000,000 shares authorized; 82,498,213 shares issued and outstanding at June 30, 2017; 83,303,628 shares issued and outstanding at December 31, 2016	1			1
Preferred stock, $0.0001 par value, 100,000,000 shares authorized, zero shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively	—			—
Commitments and contingencies (Note 6)
Stockholders’ equity:
Common stock, $0.000005 par value, 900,000,000 shares authorized, zero shares issued and outstanding at each of March 31, 2018 and December 31, 2017, respectively							—			—
Class A common stock, $0.000005 par value, 750,000,000 shares authorized; 78,566,507 shares issued and 63,946,332 shares outstanding at March 31, 2018; 77,588,018 shares issued and 62,967,843 shares outstanding at December 31, 2017							—			—
Class B common stock, $0.000005 par value, 150,000,000 shares authorized; 80,608,685 shares issued and outstanding at March 31, 2018; 80,957,495 shares issued and outstanding at December 31, 2017							1			1
Preferred stock, $0.0001 par value, 100,000,000 shares authorized, zero shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively							—			—
Additional paid-in-capital	526,363			516,300			538,873			534,159
Retained earnings	283,215			274,087			292,801			308,905
Treasury stock, Class A common stock, at cost, 11,205,992 and 7,508,985 shares at June 30, 2017 and December 31, 2016, respectively	(151,404		)	(106,231		)
Treasury stock, at cost, 14,620,175 shares at March 31, 2018 and December 31, 2017, respectively							(199,817		)	(199,817		)
Other comprehensive loss	(369		)	(580		)	(97		)	(476		)
Total stockholders' equity	657,806			683,577
Total liabilities and stockholders' equity	$	1,019,695		$	1,053,344
Total stockholders’ equity							631,761			642,772
Total liabilities and stockholders’ equity							$	975,556		$	995,078

See notes to condensed consolidated financial statements.

INOVALON HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF ~~INCOME~~OPERATIONS

(Unaudited, in thousands, except per-share amounts)


	Three Months Ended June 30,						Six Months Ended June 30,						Three Months Ended March 31,
	2017			2016			2017			2016			2018			2017
Revenue	$	110,578		$	123,825		$	218,884		$	226,482		$	92,755		$	108,306
Expenses:
Cost of revenue(1)	37,198			43,214			75,483			85,137
Sales and marketing(1)	8,849			6,116			16,436			12,675
Research and development(1)	7,282			7,711			15,070			13,643
General and administrative(1)	35,874			31,461			71,719			68,013
Cost of revenue⁽¹⁾													33,491			38,285
Sales and marketing⁽¹⁾													7,902			7,587
Research and development⁽¹⁾													6,421			7,788
General and administrative⁽¹⁾													49,396			35,845
Depreciation and amortization	12,479			8,496			24,964			16,890			16,380			12,485
Total operating expenses	101,682			96,998			203,672			196,358			113,590			101,990
Income from operations	8,896			26,827			15,212			30,124
(Loss) Income from operations													(20,835		)	6,316
Other income and (expenses):
Realized losses on short-term investments	—			(1		)	—			(5		)	(1,035		)	—
(Loss) Gain on disposal of equipment	(138		)	—			(138		)	534
Loss on disposal of equipment													(85		)	—
Interest income	1,342			1,532			2,680			2,974			1,395			1,338
Interest expense	(1,519		)	(1,245		)	(2,932		)	(2,504		)	(1,882		)	(1,413		)
Income before taxes	8,581			27,113			14,822			31,123
Provision for income taxes	3,095			10,862			5,694			12,507
Net income	$	5,486		$	16,251		$	9,128		$	18,616
Net income attributable to common stockholders, basic and diluted	$	5,338		$	16,179		$	8,913		$	18,537
Net income per share attributable to common stockholders, basic and diluted:
Basic net income per share	$	0.04		$	0.11		$	0.06		$	0.12
Diluted net income per share	$	0.04		$	0.11		$	0.06		$	0.12
(Loss) Income before taxes													(22,442		)	6,241
(Benefit from) Provision for income taxes													(5,608		)	2,599
Net (loss) income													$	(16,834	)	$	3,642
Net (loss) income attributable to common stockholders, basic and diluted													$	(16,272	)	$	3,569
Net (loss) income per share attributable to common stockholders, basic and diluted:
Basic net (loss) income per share													$	(0.12	)	$	0.02
Diluted net (loss) income per share													$	(0.12	)	$	0.02
Weighted average shares of common stock outstanding:
Basic	142,632			151,712			143,680			151,497			139,378			144,729
Diluted	143,072			152,706			144,123			152,548			139,378			145,165

(1) Includes stock-based compensation expense as follows:

Cost of revenue $ 410
$ 121
$ 715
$ 240
Sales and marketing 505
152
895
306
Research and development 307
499
580
741
General and administrative 2,525
1,364
5,154
2,941
Total stock-based compensation expense $ 3,747
$ 2,136
$ 7,344
$ 4,228



(1)	Includes stock-based compensation expense as follows:
	Cost of revenue	$	140	$	305
	Sales and marketing	469		390
	Research and development	628		273
	General and administrative	2,511		2,629
	Total stock-based compensation expense	$	3,748	$	3,597

See notes to condensed consolidated financial statements.

INOVALON HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited, in thousands)

Three Months Ended
June 30, Six Months Ended
June 30,
2017 2016 2017 2016
Net income $ 5,486
$ 16,251
$ 9,128
$ 18,616
Other comprehensive income:
Realized losses on short-term investments reclassified from accumulated other comprehensive income, net of tax of $0, ($1), $0 and ($2), respectively —
—
—
3
Net change in unrealized gains on available-for-sale investments, net of tax of $136, ($1,242), $272 and ($1,802), respectively 35
133
211
2,518
Comprehensive income $ 5,521
$ 16,384
$ 9,339
$ 21,137



	Three Months Ended March 31,
	2018			2017
Net (loss) income	$	(16,834	)	$	3,642
Other comprehensive income:
Realized losses on short-term investments reclassified from accumulated other comprehensive income, net of tax of $(319) and $0, respectively	716			—
Net change in unrealized (losses) and gains on available-for-sale investments, net of tax of $105 and $138, respectively	(235		)	176
Reclassification of income tax effects of the Tax Cuts and Jobs Act of 2017	(102		)	—
Comprehensive (loss) income	$	(16,455	)	$	3,818

See notes to condensed consolidated financial statements.

INOVALON HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, in thousands)


	Six Months Ended June 30,						Three Months Ended March 31,
	2017			2016			2018			2017
Cash flows from operating activities:
Net income	$	9,128		$	18,616
Net (loss) income							$	(16,834	)	$	3,642
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation expense	7,344			4,228			3,748			3,597
Depreciation	17,442			13,236			12,529			8,874
Amortization of intangibles	7,522			3,654			3,851			3,611
Amortization of premiums on short-term investments	1,017			1,752			232			591
Realized losses on short-term investments	—			5			1,035			—
Tax payments for equity award issuances	—			95
Deferred income taxes	(2,513		)	(654		)	(5,922		)	(113		)
Excess tax benefits from stock-based compensation	—			(1,068		)
Loss (Gain) on disposal of equipment	138			(534		)
Loss on disposal of equipment							85			—
Change in fair value of contingent consideration							200			—
Changes in assets and liabilities:
Accounts receivable	(10,107		)	(13,467		)	11,669			(16,049		)
Prepaid expenses and other current assets	683			(960		)	(2,560		)	(886		)
Income taxes receivable	7,328			9,471			177			2,381
Other assets	(2,313		)	56			(3,264		)	(890		)
Accounts payable	5,660			(7,655		)	(1,669		)	69
Accrued compensation	112			(228		)	(4,017		)	(6,467		)
Other liabilities	114			5,262			2,164			(816		)
Deferred rent	(446		)	(352		)	335			(214		)
Deferred revenue	10			949			5,115			5,001
Net cash provided by operating activities	41,119			32,406			6,874			2,331
Cash flows from investing activities:
Sales and maturities of short-term investments	105,245			164,767
Purchases of short-term investments	—			(132,157		)
Maturities of short-term investments							63,470			59,615
Sales of short-term investments							161,772			—
Purchases of property and equipment	(9,180		)	(8,263		)	(9,645		)	(2,965		)
Investment in capitalized software	(15,394		)	(8,849		)	(11,125		)	(5,605		)
Net cash provided by investing activities	80,671			15,498			204,472			51,045
Cash flows from financing activities:
Repurchase of common stock	(45,173		)	—			—			(25,383		)
Repayment of credit facility borrowings	(15,000		)	(7,500		)	(11,250		)	(7,500		)
Proceeds from exercise of stock options	3,016			4,415			1,450			25
Capital lease obligations paid	(58		)	(31		)	(31		)	(116		)
Tax payments for equity award issuances	(246		)	(95		)	(459		)	(197		)
Excess tax benefits from stock-based compensation	—			1,068
Net cash used in financing activities	(57,461		)	(2,143		)	(10,290		)	(33,171		)
Increase in cash and cash equivalents	64,329			45,761			201,056			20,205
Cash and cash equivalents, beginning of period	127,683			114,034			208,944			127,683
Cash and cash equivalents, end of period	$	192,012		$	159,795		$	410,000		$	147,888
Supplementary cash flow disclosure:
Cash paid during the period for:
Income taxes, net of refunds	$	379		$	3,594		$	205		$	189
Interest	2,840			2,380			1,759			1,364
Non-cash investing activities:
Capital lease obligations incurred							4,536			—
Accruals for purchases of property, equipment	4,773			376			6,675			2,737
Accruals for investment in capitalized software	1,302			226			1,882			2,992

See notes to condensed consolidated financial statements.

INOVALON HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared by Inovalon Holdings, Inc. (the ~~"Company"~~“Company”) in accordance with accounting principles generally accepted in the United States ~~("GAAP"~~(“GAAP”) for interim financial reporting and as required by Rule 10-01 of Regulation S-X. Accordingly, the unaudited condensed consolidated financial statements may not include all of the information and notes required by GAAP for audited financial statements. The year-end December 31, ~~2016~~2017 condensed consolidated balance sheet data included herein was derived from audited financial statements but does not include all disclosures required by GAAP for complete financial statements. In the opinion of the ~~Company's~~Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of items of a normal and recurring nature, necessary to present fairly the ~~Company's~~Company’s financial position as of ~~June 30, 2017,~~March 31, 2018, the results of operations and comprehensive income for the three ~~and six~~ month periods ended ~~June 30,~~March 31, 2018 and 2017, ~~and 2016,~~ and cash flows for the ~~six~~three months ended ~~June 30, 2017~~March 31, 2018 and ~~2016.~~2017. The results of operations for the three ~~and six~~ month periods ended ~~June 30,~~March 31, 2018 and 2017 ~~and 2016~~ are not necessarily indicative of the results to be expected for the full year. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities, and related disclosures, as of the date of the financial statements, and the amounts of revenue and expenses reported during the period. Actual results could differ from estimates. The information contained herein should be read in conjunction with the audited financial statements included in the ~~Company's~~Company’s Annual Report on Form 10-K for the year ended December 31, ~~2016~~2017 (the ~~"2016~~“2017 Form ~~10-K"~~10-K”).

Certain prior period amounts have been reclassified within the operating section of the condensed consolidated statements of cash flows, and within the investing section of the statements of cash flows to conform with current period presentation. Such reclassifications had no impact on net cash provided by operating activities or net cash provided by (used in) investing activities as previously reported.

The accompanying unaudited condensed consolidated financial statements include the accounts of Inovalon Holdings, Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

The ~~Company's~~Company’s management considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through the date of issuance of these financial statements.

Recently ~~Issued~~Adopted Accounting Standards

There have been no developments to recently issued accounting standards, including the expected dates of adoption and estimated effects on the Company's consolidated financial statements and note disclosures, from those disclosed in the 2016 Form 10-K, that would be expected to impact the Company except for the following:

In May 2014, the Financial Accounting Standards Board ~~("FASB"~~(“FASB”) issued ~~ASU~~Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customersand subsequent clarifying guidance ("(“ASU ~~2014-09"~~2014-09”). ~~This revenue recognition guidance supersedes existing GAAP guidance, including most industry-specific guidance.~~ The core principle is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted this standard on January 1, 2018 using the modified retrospective approach. Refer to Note 2, “Revenue.”

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). The update amends the guidance ~~identifies five steps~~in Accounting Standards Codification (“ASC”) 230, Statement of Cash Flows, and clarifies how entities should classify certain cash receipts and cash payments on the statement of cash flows with the objective of reducing the existing diversity in practice related to apply in achieving this principle. ASU 2014-09 is effective for fiscal years beginning after December 15, 2017. ASU 2014-09 may be applied either retrospectively or through the use of a modified-retrospective method.eight specific cash flow issues. The Company is in the process of finalizing our contract review at which point, the Company will evaluate the method of adoption, the impact to the consolidated financial statements, changes to our systems and internal control over financial reporting in response to the new standard. The Company anticipates that this standard may have a material impact on the consolidated financial statements with respect to additional disclosures related to qualitative and quantitative information concerning the nature, amount, timing, and any uncertainty of revenue and cash flows from contracts with customers, the capitalization of costs of commissions, upfront contract costs, and other contract acquisition-based and contract fulfillment costs on the consolidated balance sheets. The Company expects to make a determination as to the timing and method of adoption in the second half of 2017 and will adoptadopted the requirements of the new standard in the first quarter of ~~2018.~~2018 and there was no material impact on its consolidated financial statements.

In ~~January 2017,~~February 2018, the FASB issued ASU ~~2017-01,~~2018-02, ~~Business Combinations~~Income Statement-Reporting Comprehensive Income (Topic ~~805)~~220): ~~Clarifying the Definition~~Reclassification of ~~a Business.~~Certain Tax Effects from Accumulated Other Comprehensive Income. The ~~new standard narrows the definition of a business and provides a framework for evaluation. This ASU~~guidance is effective for ~~financial statements issued~~all public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. This guidance allows for a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017 ~~including~~(the “Tax Act”) which was signed into law on December 22, 2017. Early adoption is permitted in any interim ~~periods within those~~period or fiscal ~~years.~~year before the effective date. The Company early adopted the requirements of the new standard in the first quarter of 2018, and elected to reclassify the income tax effects of the Tax Act of $0.1 million from other comprehensive income to retained earnings. Refer to the condensed consolidated statements of comprehensive income.

Recently Issued Accounting Standards

There have been no developments to recently issued accounting standards, including the expected dates of adoption and estimated effects on the Company’s consolidated financial statements and note disclosures, from those disclosed in the 2017 Form 10-K, that would be expected to impact the Company except for the following:

In ~~January~~August 2017, the FASB issued ASU ~~2017-04,~~2017-12, ~~Intangibles—Goodwill~~Derivatives and ~~Other~~Hedging (Topic ~~350): Simplifying the Test~~815)-Targeted Improvements to Accounting for ~~Goodwill Impairment.~~Hedging Activities. The update amends the current hedge accounting model and eliminates the requirement to separately measure and report hedge ineffectiveness. This guidance also requires, for qualifying hedges, the entire change in the fair value of a hedging instrument to be presented in the same income statement line item as the hedged item. The update also eases documentation and assessment requirements, modifies certain disclosure requirements, and modifies the method of accounting for components excluded from the assessment of hedge effectiveness. The Company plans to adopt the requirements of the new standard ~~simplifies the subsequent measurement of goodwill by eliminating~~in the second ~~step~~quarter of ~~the goodwill impairment test. This ASU will be applied prospectively and is effective for annual or interim goodwill~~2018.

~~impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017.~~

2. REVENUE

The Company adopted ASU 2014-09 as of January 1, 2018 using the modified retrospective approach. Revenues for periods beginning after January 1, 2018 are presented under Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under ASC 605. The Company recorded a cumulative effect net adjustment to increase retained earnings by $0.6 million as of January 1, 2018. The impact as a result of adopting ASC 606 was an increase of $0.2 million in revenue and an increase of $0.1 million in expense resulting from deferred commissions for the three months ended March 31, 2018.

These adjustments primarily related to commissions for certain contracts which are now expensed over the remaining life of the contracts and credits provided to customers which are recorded as a reduction to revenue over the applicable service period. For the remaining contracts, the Company has elected to use the practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that the entity otherwise would have recognized is one year or less.

The Company primarily derives its revenues through the sale or subscription licensing of its platform solutions and services. The following table disaggregates revenue by offering (in thousands):



	Three Months Ended March 31,
	2018		2017⁽¹⁾
Platform solutions⁽²⁾	$	78,966	$	91,432
Services⁽³⁾	13,789		16,874
Total revenue	$	92,755	$	108,306


(1)	Prior period amounts have not been adjusted under the modified retrospective method.


(2)	Platform solutions include arrangements for technology-based offerings representing subscription-based cloud-based platform offerings and legacy platform solutions that are not cloud-based and not billed under a subscription-based contract structure.


(3)	Services include advisory, implementation, and support services under time and materials, fixed price, or retainer-based contracts.

Performance Obligations

A performance obligation is a contractual promise to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation based on standalone selling price and revenue is recognized when the performance obligations under the terms of a contract are satisfied. The determination of standalone selling price for each performance obligation requires judgment based on the terms of the contract.

The majority of the Company’s platform solutions contracts contain a series of separately identifiable and distinct services that represent performance obligations that are satisfied over time. The Company allocates revenue to platform solutions by determining the standalone selling price of each performance obligation. Revenue is generally recognized on our platform offerings over the contract term. For certain contracts, the Company has determined that it will use the practical expedient under ASC 606-10-55-18 to recognize revenue when it has the right to invoice. The Company qualifies for this practical expedient because the right to invoice corresponds directly with the value transferred to the customer.

The Company allocates revenue to its service arrangements for advisory, implementation, and support services based on contractually agreed upon billing rates applied to direct labor hours expended plus the costs of other items used in the performance of the contract. The Company concluded that it will recognize revenue when it has the right to invoice the customer using the allowable practical expedient since the right to invoice the customer corresponds with the performance obligations completed. Revenues under fixed-price and retainer-based contracts are recognized ratably over the contract period or upon contract completion.

Certain of the Company’s arrangements entitle a client to receive a refund if the Company fails to satisfy contractually specified performance obligations. The refund is limited to a portion or all of the consideration paid. In this case, revenue is recognized when performance obligations are satisfied. Historically, the Company has met contractually specified performance obligations.

Contract Balances

The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables, and deferred revenue. Invoices to clients are generated in accordance with the terms of the applicable contract, which may not be directly related to the performance of services. Unbilled receivables are invoiced when the achievement of specific events as defined by each contract occurs. The Company had unbilled receivables of $11.4 million and $14.1 million as of March 31, 2018 and December 31, 2017, respectively. Unbilled receivables are classified as accounts receivable on the condensed consolidated balance sheet. Advanced billings to clients in excess of revenue earned are recorded as deferred revenue until the aforementioned revenue recognition criteria are met.

Revenue recognized during the three months ended March 31, 2018, that was included in the deferred revenue balance at the beginning of the year, was $1.8 million.

3.NET (LOSS) INCOME PER SHARE~~(in thousands, except per share amounts)~~

Holders of all outstanding classes of common stock participate ratably in earnings on an identical per share basis as if all shares were a single class. Basic earnings per share ~~("EPS"~~(“EPS”) is computed by dividing net (loss) income by the weighted average number of shares of common stock (Class A common stock and Class B common stock) outstanding during the period. Diluted EPS is computed by dividing net income by the sum of the weighted average number of shares of common stock outstanding and potentially dilutive securities outstanding during the period under the treasury stock method. If the Company incurs a loss from continuing operations, diluted EPS is computed in the same manner as basic EPS. Potentially dilutive securities include stock options, restricted stock units ~~("RSUs"~~(“RSUs”) and restricted stock awards ~~("RSAs"~~(“RSAs”). Under the treasury stock method, dilutive securities are assumed to be exercised at the beginning of the periods and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Securities are excluded from the computations of diluted earnings per share if their effect would be anti-dilutive to EPS.

The Company has issued RSAs under the 2015 Omnibus Incentive Plan. The Company considers issued and unvested RSAs to be participating securities as the holders of these RSAs have a non-forfeitable right to dividends in the event of the ~~Company's~~Company’s declaration of a dividend on shares of Class A and Class B common stock. Subsequent to the issuance of the participating securities, the Company applied the two-class method required in calculating net (loss) income per share of Class A and Class B common stock. Under the two-class method, net income attributable to common stockholders is determined by allocating undistributed earnings, calculated as net income, less earnings attributable to participating securities. The net (loss) income per share attributable to common stockholders is allocated based on the contractual participation rights of the Class A common stock and Class B common stock as if the (loss) income for the period has been distributed. As the liquidation and dividend rights are identical for both classes of common stock, the net (loss) income attributable to common stockholders is allocated on a proportionate basis.

The following table reconciles the weighted average shares outstanding for basic and diluted EPS for the periods ~~indicated:~~indicated (in thousands, except per share amounts):


	Three Months Ended June 30,						Six Months Ended June 30,						Three Months Ended March 31,
	2017			2016			2017			2016			2018			2017
Basic
Numerator:
Net income	$	5,486		$	16,251		$	9,128		$	18,616
Undistributed earnings allocated to participating securities	(148		)	(72		)	(215		)	(79		)
Net income attributable to common stockholders	$	5,338		$	16,179		$	8,913		$	18,537
Net (loss) income													$	(16,834	)	$	3,642
Undistributed loss (earnings) allocated to participating securities													562			(73		)
Net (loss) income attributable to common stockholders—basic													$	(16,272	)	$	3,569
Denominator:
Weighted average shares used in computing net income per share attributable to common stockholders—basic	142,632			151,712			143,680			151,497			139,378			144,729
Net income per share attributable to common stockholders—basic	$	0.04		$	0.11		$	0.06		$	0.12
Net (loss) income per share attributable to common stockholders—basic													$	(0.12	)	$	0.02
Diluted
Numerator:
Net income attributable to common stockholders	$	5,338		$	16,179		$	8,913		$	18,537
Net (loss) income attributable to common stockholders—diluted													$	(16,272	)	$	3,569
Denominator:
Number of shares used for basic EPS computation	142,632			151,712			143,680			151,497			139,378			144,729
Effect of dilutive securities	440			994			443			1,051			—			436
Weighted average shares used in computing net income per share attributable to common stockholders—diluted	143,072			152,706			144,123			152,548			139,378			145,165
Net income per share attributable to common stockholders—diluted	$	0.04		$	0.11		$	0.06		$	0.12
Net (loss) income per share attributable to common stockholders—diluted													$	(0.12	)	$	0.02

The computation of diluted EPS does not include certain ~~unvested~~ awards, on a weighted average basis, for the three ~~and six~~ months ended ~~June 30,~~March 31, 2018 and 2017, ~~and 2016, respectively,~~ because their inclusion would have an anti-dilutive effect on EPS. The awards excluded because of their anti-dilutive effect are as ~~follows:~~follows (in thousands):

Three Months Ended
June 30, Six Months Ended
June 30,
2017 2016 2017 2016
Awards excluded from the computation of diluted net income per share because their inclusion would have been anti-dilutive 135
116
213
131



	Three Months Ended March 31,
	2018	2017
Awards excluded from the computation of diluted net (loss) income per share because their inclusion would have been anti-dilutive	118	168

3.4. SHORT-TERM INVESTMENTS~~(in thousands)~~

As of ~~June 30,~~March 31, 2018, short-term investments consisted of the following (in thousands):



	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
Available-for-sale securities:
Corporate notes and bonds	$	37,401	$	—	$	(140	)	$	37,261
U.S. agency obligations	3,015		—		(1		)	3,014
Total available-for-sale securities	$	40,416	$	—	$	(141	)	$	40,275

As of December 31, 2017, short-term investments consisted of the ~~following:~~following (in thousands):


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
Available-for-sale securities:
Corporate notes and bonds	$	291,494	$	65	$	(454	)	$	291,105	$	232,048	$	3	$	(572	)	$	231,479
U.S. agency obligations	27,857		3		(53		)	27,807		15,341		—		(99		)	15,242
U.S. treasury securities	20,736		—		(112		)	20,624		20,735		—		(168		)	20,567
Total available-for-sale securities	$	340,087	$	68	$	(619	)	$	339,536	$	268,124	$	3	$	(839	)	$	267,288

~~As of December 31, 2016, short-term investments consisted of the following:~~

Amortized
Cost

Gross Unrealized
Gains

Gross
Unrealized
Losses

Estimated Fair
Value
Available-for-sale securities:

Corporate notes and bonds $ 349,571
$ 36
$ (918 ) $ 348,689
U.S. agency obligations 34,864
22
(78 ) 34,808
U.S. treasury securities 53,681
6
(100 ) 53,587
Commercial paper 6,312
—
(3 ) 6,309
Certificates of deposit 1,921
1
—
1,922
Total available-for-sale securities $ 446,349
$ 65
$ (1,099 ) $ 445,315

The following table summarizes the estimated fair value of our short-term investments, designated as available-for-sale and classified by the contractual maturity date of the securities as of the dates ~~shown:~~shown (in thousands):


	June 30, 2017		December 31, 2016		March 31, 2018		December 31, 2017
Due in one year or less	$	192,204	$	176,696	$	38,484	$	204,725
Due after one year through three years	147,332		268,619
Due after one year through two years					1,791		62,563
Total	$	339,536	$	445,315	$	40,275	$	267,288

The Company has certain available-for-sale securities in a gross unrealized loss position. The Company reviews its debt securities classified as short-term investments on a regular basis to evaluate whether or not any security has experienced an other-than-temporary decline in fair value. The Company considers factors such as the length of time and extent to which the market value has been less than the cost, the financial position and near-term prospects of the issuer and the ~~Company's~~Company’s intent to sell, or whether it is more likely than not the Company will be required to sell the investment before recovery of the ~~investment's~~investment’s amortized-cost basis. If the Company determines that an other-than-temporary decline exists, or if write downs related to credit losses are necessary, in one of these securities, the unrealized losses attributable to the respective investment would be reclassified to realized losses on short-term investments within the statement of operations. There were no impairments considered other-than-temporary as of ~~June 30, 2017.~~

March 31, 2018.

The following table shows the fair values and the gross unrealized losses of available-for-sale securities that were in a gross unrealized loss position, as of ~~June 30, 2017,~~March 31, 2018, aggregated by investment ~~category:~~category (in thousands):


	Estimated Fair Value		Gross Unrealized Losses			Estimated Fair Value		Gross Unrealized Losses
Corporate notes and bonds	$	225,931	$	(454	)	$	37,261	$	(140	)
U.S. agency obligations	17,795		(53		)	3,014		(1		)
U.S. treasury securities	20,624		(112		)
	$	264,350	$	(619	)	$	40,275	$	(141	)

4.5. FAIR VALUE MEASUREMENTS ~~(in thousands)~~

The following table presents the fair value hierarchy for financial assets and liabilities measured at fair value on a recurring basis as of ~~June 30, 2017:~~March 31, 2018 (in thousands):


	Level 1		Level 2		Level 3			Total			Level 1		Level 2		Level 3			Total
Cash Equivalents:
Money market funds	$	61,707	$	—	$	—		$	61,707		$	138	$	—	$	—		$	138
Short-term investments:
Corporate notes and bonds	—		291,104		—			291,104			—		37,261		—			37,261
U.S. agency obligations	—		27,808		—			27,808			—		3,014		—			3,014
U.S. treasury securities	—		20,624		—			20,624
Certificates of deposit	—		—		—			—
Liabilities:
Contingent consideration	—		—		(13,900		)	(13,900		)	—		—		(7,600		)	(7,600		)
Total	$	61,707	$	339,536	$	(13,900	)	$	387,343		$	138	$	40,275	$	(7,600	)	$	32,813

The following table presents the fair value hierarchy for financial assets and liabilities measured at fair value on a recurring basis as of December 31, ~~2016:~~2017 (in thousands):


	Level 1		Level 2		Level 3			Total			Level 1		Level 2		Level 3			Total
Cash Equivalents:
Money market funds	$	44,108	—		—			$	44,108		$	162,347	$	—	$	—		$	162,347
Short-term investments:
Corporate notes and bonds	—		348,689		—			348,689			—		231,479		—			231,479
U.S. agency obligations	—		34,808		—			34,808			—		15,242		—			15,242
U.S. treasury securities	—		53,587		—			53,587			—		20,567		—			20,567
Commercial paper	—		6,309		—			6,309
Certificates of deposit	—		1,922		—			1,922
Other Current Liabilities:
Contingent consideration	—		—		(12,600		)	(12,600		)	—		—		(7,400		)	(7,400		)
Total	$	44,108	$	445,315	$	(12,600	)	$	476,823		$	162,347	$	267,288	$	(7,400	)	$	422,235

The Company determines the fair value of its security holdings based on pricing from its pricing vendors. The valuation techniques used to measure the fair value of financial instruments having Level 2 inputs were derived from non-binding consensus prices that are corroborated by observable market data or quoted market prices for similar instruments. Such market prices may be quoted prices in active markets for identical assets (Level 1 inputs) or pricing determined using inputs other than quoted prices that are observable either directly or indirectly (Level 2 inputs). The Company performs procedures to ensure that appropriate fair values are recorded such as comparing prices obtained from other sources.

The following table presents our financial instruments measured at fair value using unobservable inputs (Level 3) (in thousands):

Fair Value
Measurements Using
Unobservable Inputs
(Level 3)
June 30,
2017 December 31,
2016
Balance, beginning of period $ (12,600 ) $ (2,300 )
Accretion expense (recognized in general and administrative expenses) (1,300 ) (706 )
Settlement (payment) of liability —
3,006
Contingent consideration attributable to Creehan acquisition —
(12,600 )
Total $ (13,900 ) $ (12,600 )



	Fair Value Measurements Using Unobservable Inputs (Level 3)
	March 31, 2018			December 31, 2017
Balance, beginning of period	$	(7,400	)	$	(12,600	)
Fair value adjustment (recognized in general and administrative expenses)	(200		)	5,200
Total	$	(7,600	)	$	(7,400	)

5.6. COMMITMENTS AND CONTINGENCIES~~(in thousands)~~

Legal Proceedings—From time to time the Company is involved in various litigation matters arising out of the normal course of business. The Company consults with legal counsel on those issues related to litigation and seeks input from other experts and advisors with respect to such matters. Estimating the probable losses or a range of probable losses resulting from litigation, government actions and other legal proceedings is inherently difficult and requires an extensive degree of judgment, particularly where the matters involve indeterminate claims for monetary damages, may involve discretionary amounts, present novel legal theories, are in the early stages of the proceedings, or are subject to appeal. Whether any losses, damages or remedies ultimately resulting from such matters could reasonably have a material effect on the ~~Company's~~Company’s business, financial condition, results of operations, or cash flows will depend on a number of variables, including, for example, the timing and amount of such losses or damages (if any) and the structure and type of any such remedies. The ~~Company's~~Company’s management does not presently expect any litigation matters to have a material adverse impact on the condensed consolidated financial statements of the Company.

~~On June 24, 2016, a purported securities class action complaint (Xiang v. Inovalon Holdings, Inc., et.al., No. 1:16-cv-04923) was filed in~~There have been no significant or material developments to current legal proceedings, including the United States District Court for the Southern District of New York against the Company, certain officers, directors and underwriters in the Company's initial public offering (the "Complaint"). The Complaint was broughtestimated effects on behalf of a purported class consisting of all persons or entities who purchased shares of the Company's Class A common stock pursuant or traceable to the Registration Statement relating to the Company's initial public offering on February 18, 2015. The Complaint asserted violations of Sections 11 and 15 of the Securities Act based on allegedly false or misleading statements and omissions with respect to, among other things, the Company's revenues from sales in the city and state of New York and the Company's effective tax rate. The Complaint sought certification as a class action and unspecified compensatory damages plus interest and attorneys' fees. On June 28, 2016, a nearly identical complaint was filed in the same court captioned ~~Patel v. Inovalon Holdings, Inc., et. al., No. 1:16-cv-05065. On July 5, 2016, the court consolidated the~~ ~~Xiang~~ ~~and~~ ~~Patel~~ actions. On September 20, 2016, the court appointed a lead plaintiff and lead counsel. On December 21, 2016, lead plaintiff filed a consolidated class action complaint (the "Amended Complaint") purporting to assert violations of Sections 11, 12(a)(2), and 15 of the Securities Act of 1933, as amended, based on allegedly false or misleading statements and omissions with respect to substantially the same topics as alleged in the Complaint. On February 21, 2017, and as required by the court's individual practices, the Company invoked the pre-motion process required prior to filing a motion to dismiss. On May 23, 2017, the court issued a decision and order construing the pre-motion letter submitted by the defendants as a motion to dismiss, granting dismissal of the Section 12 claims against the individual defendants, but denying dismissal of the remaining claims. On June 6, 2017, defendants filed a joint motion for reconsideration and supporting memorandum of law seeking reconsideration of the court’s decision and arguing that plaintiff’s claims are time-barred. Also on June 6, 2017, defendants submitted a letter to the court requesting, in the alternative to the motion for reconsideration, a pre-motion conference concerning defendants’ anticipated motion for certification of an interlocutory appeal to resolve a controlling question of law. The motion for reconsideration and letter seeking a pre-motion conference are both still pending before the court. On July 11, 2017, the Company and its officers and directors filed their answer to the Amended Complaint denying that plaintiffs are entitled to any relief. On July 28, 2017, the court issued a decision and order denying both the motion for reconsideration and defendant’s request for an interlocutory appeal. In light of, among other things, the early stage of the litigation, the Company is unable to predict the outcome of these consolidated actions and is unable to make a meaningful estimate of the amount or range of loss, if any, that could result from this proceeding.

~~On February 16, 2017, an order was entered unsealing a relator's civil False Claims Act qui tam complaint in the matter of~~ ~~U.S. ex rel. Benjamin Poehling~~, ~~individually~~ (Civil Action No: 11-cv-0258-A). The action was filed on October 27, 2011 in the Western District of New York. The case names 15 defendants, one of which is MedAssurant, Inc., the Company's former name, and cites the allegedly fraudulent submission of claims for and alleged false statements relating to risk adjustment

payments under the federal Medicare program as the basis for the suit. The Company was not aware prior to February 16, 2017, that it was named as one of 15 defendants in this case until the complaint was unsealed. On May 16, 2017, the plaintiff and the U.S. government filed amended complaints. The Company was not named as a defendant in the amended complaints filed on May 16, 2017.

~~On June 29, 2017, Virginia Rodriquez filed a putative shareholder derivative suit in the Supreme Court of the State of New York, County of Westchester, against certain of~~ the Company’s present and former directors and officers (the “Derivative Complaint”). The Company was named as a nominal defendant. The Derivative Complaint makes allegations similar to the allegations in the securities class action Amended Complaint described above and asserts claims for breach of fiduciary duty, unjust enrichment, abuse of control and gross mismanagement, and seeks unspecified damages, an order directing the Company "to reform and improve" certain corporate governance and internal procedures, restitution from the defendants and disgorgement of all profits, benefits and other compensation received and costs and disbursements incurred in connection with the action, including attorneys' fees. The Company is a nominal defendant in the derivative action and, in light of, among other things, the early stage of the litigation, the Company is unable to predict the outcome of this action and is unable to make a meaningful estimate of the amount or range of loss, if any, that could result from this proceeding.

6.~~BUSINESS COMBINATIONS(in thousands, except share amounts)~~

~~Creehan Acquisition~~

On October 3, 2016, the Company completed its acquisition of Creehan Holding Co., Inc. ("Creehan"). Creehan, through its subsidiary Creehan & Company Corporation, is a leading provider of specialty pharmacy software solutions to the pharmaceutical industry. Pursuant to the terms of the Stock Purchase Agreement between the Company and Creehan (the "Stock Purchase Agreement"), Creehan became a wholly owned subsidiary of Inovalon.

Pursuant to the terms of the Stock Purchase Agreement, Inovalon acquired all of the issued and outstanding capital stock of Creehan for an aggregate purchase price of $130 million, which was comprised of $120 million in cash and $10 million in shares of Class A common stock of the Company. The Company completed the acquisition of Creehan through the use of cash on hand and the issuance of 651,355 shares of Class A common stock, subject to resale restrictions. Certain components, which are referred to below as contingent consideration, of the aggregate purchase price are subject to the achievement of financial performance objectives. The Company acquired Creehan for the assembled workforce, technology platform, client base, and to accelerate entry into the specialty pharmacy software market. Transaction costs in connection with the acquisition are expensed as incurred and are included in general and administrative expenses. The results of operations related to Creehan are included in our consolidated statements of operations beginning from the date of acquisition.

~~A summary of the preliminary composition of the stated purchase price and fair value of the stated purchase price is as follows:~~

Share Purchase Agreement purchase price $ 130,000
Working capital adjustment 755
Subtotal 130,755
Fair value adjustments:
Marketability restrictions on equity consideration (2,236 )
Contingent consideration probability of achievement adjustment. (12,400 )
Post-acquisition compensation expense (5,952 )
Total fair value purchase price $ 110,167

During the six months ended June 30, 2017, the Company finalized the working capital adjustment resulting in an increase to goodwill of approximately $1 million from the initial purchase price allocation. After adjusting for this difference the composition of the fair value of the consideration transferred is as follows:

Cash $ 89,370
Issuance of Class A common stock 7,764
Working capital adjustment payable 433
Contingent consideration 12,600
Total fair value purchase price $ 110,167

~~Recording of Assets Acquired and Liabilities Assumed~~

~~Preliminary estimates of fair value included in the~~condensed consolidated financial statements and note disclosures, subsequent to the disclosure previously provided in ~~conformity with ASC No. 820,~~ ~~Fair Value Measurements and Disclosures, represent the Company's best preliminary estimates and preliminary valuations. In accordance with ASC No. 805,~~ ~~Business Combinations, the preliminary allocation~~Note 10 of the ~~consideration value is subject~~Notes to ~~adjustment until~~ the Company has completed its analysis, but not to exceed one year after the date of acquisition, which was October 3, 2016, to provide the Company with the time to complete the valuation of its assets and liabilities. As of June 30, 2017, the Company wasConsolidated Financial Statements in the process of reviewing its assumptions related to (a) the finalization of assumptions used to determine the fair value of acquired deferred revenue liabilities, and (b) the finalization of estimates of tax related matters. If the previously identified matters are significant, changes to the Company's allocation of the consideration value to assets acquired and liabilities assumed could result as well as changes concerning amortization expense and revenue.

~~The following table summarizes the preliminary purchase price allocation to assets acquired and liabilities assumed, including identification of measurement period adjustments:~~

Preliminary
Recorded
Value
Cash and cash equivalents $ 861
Accounts receivable 9,048
Other current assets 171
Property, equipment and capitalized software 641
Intangible assets(1) 50,900
Goodwill(2) 51,989
Total assets acquired 113,610
Current liabilities (1,007 )
Deferred revenue (2,436 )
Total liabilities assumed (3,443 )
Net assets acquired $ 110,167


~~(1)~~	~~Identifiable intangible assets were measured using a combination of an income approach and a market approach.~~


~~(2)~~	Goodwill is the excess of the consideration transferred over the net assets recognized and represents the future economic benefits, primarily as a result of other assets acquired that could not be individually identified and separately recognized. Goodwill is not amortized. The goodwill attributable to the Creehan acquisition is deductible for tax purposes.

~~The amounts preliminarily attributed to identified intangible assets are summarized in the table below:~~

Weighted
Average
Useful Life

Recorded
Value
Customer relationships 8 years $ 36,500
Tradename 4 years 4,000
Technology 4 years 8,800
In-process Research and Development indefinite 1,600
Total intangible assets $ 50,900

~~The following table summarizes the activity related to the carrying value of our goodwill during the six months ended June 30, 2017:~~

Goodwill as of January 1, 2017 $ 184,557
Measurement period adjustments 1,002
Goodwill as of June 30, 2017 $ 185,559
2017 Form 10-K.

7. ~~STOCKHOLDERS' EQUITY(in thousands, except share amounts and share price)~~BUSINESS COMBINATIONS

~~Treasury Stock~~—On May 4, 2016, the Company announced that its Board of Directors authorized a program to repurchase up to $100 million of Inovalon's Class A common stock through December 31, 2016. Repurchases under theComplexCare Solutions Acquisition

Company's share repurchase program have been made in open-market or privately negotiated transactions. The Company has and expects to continue to fund repurchases through a combination of cash on hand, cash generated by operations and sales of short-term investments, if needed. On November 2, 2016, the Company announced that its Board of Directors authorized an expansion of the share repurchase program to repurchase up to an additional $100 million of shares of Inovalon's Class A Common Stock (bringing the total to $200 million) through December 31, 2017. The share repurchase program does not obligate the Company to acquire any particular amount of Class A common stock.

During the three months ended June 30, 2017, the Company repurchased 1,555,606 shares of Class A common stock for an aggregate cost of $19,789 at an average cost of $12.72 per share, excluding commissions. During the six months ended June 30, 2017, the Company repurchased 3,697,007 shares of Class A common stock, for an aggregate cost of $45,173 at an average cost of $12.22 per share, excluding commissions. At June 30, 2017, approximately $48,596 remained available to repurchase shares under the share repurchase program. Shares that are repurchased under the repurchase program were recorded as treasury stock, based on the stock trading dates, and are available for future issuance, until retired.

8.~~SUBSEQUENT EVENTS~~

~~Business Combination~~—On July 6, 2017, the Company completed the acquisition of ComplexCare Solutions, Inc. ~~("CCS"~~and ComplexCare Solutions IPA, LLC (together, “CCS”). CCS is a company ~~which~~that provides technology-enabled interventions and member engagement coordination services for a number of payers and employers throughout the United States. The fair value included in the consolidated financial statements represents the Company’s best estimates and valuations in conformity with ASC No. 820, Fair Value Measurements and Disclosures. The final purchase price was allocated to identifiable assets acquired and liabilities assumed based upon valuation procedures performed. The Company acquired all of the capital stock of CCS for approximately $3$4.5 million in cash and the ~~assumption~~

settlement of an existing payable to CCS of $2.3 million. The Company acquired approximately $9.8 million of assets, including approximately $1.5 million of cash and approximately $3.9 million of liabilities. The net assets acquired exceeded the consideration paid by approximately $1.4 million, and as such the Company recorded a bargain purchase gain in general and administrative expenses for the year ended December 31, 2017.

8.SUBSEQUENT EVENTS

Business Combination—On April 2, 2018, the Company acquired Butler Group Holdings, Inc., a Delaware corporation, and its wholly-owned subsidiaries, including, without limitation, ABILITY Network Inc., a Delaware corporation (“ABILITY”), for aggregate consideration of approximately $1.17 billion in cash and restricted shares of the Company’s Class A common stock (“the ABILITY Acquisition”).

ABILITY is a leading cloud-based Software-as-a-service (“SaaS”) technology company helping to simplify the administrative and clinical complexities of healthcare. Through the myABILITY^® software platform, an integrated set of cloud-based applications for providers, ABILITY provides core connectivity, administrative, clinical, and quality analysis, management, and performance improvement capabilities to more than 44,000 acute, post-acute and ambulatory point-of-care provider facilities. The extensive datasets, on-demand compute capability, advanced analytics, and broad healthcare ecosystem connectivity enabled by the Inovalon ONE™ Platform are expected to provide a significant expansion of application offerings within the myABILITY^® software platform while also expanding the nature and reach of high-value solutions for Inovalon’s existing payer, pharma, and device client-base. The combination of Inovalon and ABILITY creates a vertically integrated cloud-based platform empowering the achievement of real-time, value-based care from payers, manufacturers, and diagnostics all the way to the patient’s point of care.

The aggregate consideration was comprised of $1.1 billion in cash and the issuance of 7.6 million restricted shares of the Company’s Class A common stock which has a preliminary value of approximately $70.0 million using an option pricing valuation model discounted for marketability. The cash portion of the aggregate consideration was financed through a combination of cash on hand and borrowings from the 2018 Term Facility (as defined below).

The Company acquired certain intangible assets in connection with the ABILITY Acquisition including customer relationships, trade names, and technology. The purchase price allocation of assets acquired and liabilities assumed will be completed within the one year measurement period as required by ASC No. 805, Business Combinations. The preliminary value of consideration is subject to adjustment until the Company has completed its analysis within the measurement period. The Company is in the process of reviewing its assumptions related to the fair value of the consideration pending any working capital adjustments and estimates of tax related matters.

Credit Facility—In connection with the ABILITY Acquisition, on April 2, 2018, the Company entered into a credit agreement (the “2018 Credit Agreement”) with Morgan Stanley Senior Funding, Inc. (“MSSF”), as administrative agent, to provide a Credit Facility which is comprised of: (i) a term loan B facility with the Company as borrower in a total principal amount of $980.0 million (the “2018 Term Facility”); and (ii) a revolving credit facility with the Company as borrower in a total principal amount of up to $100.0 million (the “2018 Revolving Facility”). The 2018 Revolving Facility will terminate on April 2, 2023 and the 2018 Term Facility will mature on April 2, 2025. The entire $980.0 million 2018 Term Facility was borrowed on April 2, 2018, and was used to pay off all of the Company’s existing debt obligations under the Credit and Guaranty Agreement dated as of September 19, 2014 as well as to provide the financing necessary to fund, in part, the cash consideration paid pursuant to the terms of the merger agreement. As of the date hereof, the Company has not drawn any amounts under the 2018 Revolving Facility. In addition, the Company and its Restricted Subsidiaries (as defined in the 2018 Credit Agreement) are subject to certain affirmative and negative covenants under the 2018 Credit Agreement, and the 2018 Credit Agreement includes certain customary representations and warranties of the Company.

At the option of the Company, the loans outstanding under the 2018 Term Facility will bear interest either at: (i) Adjusted London Interbank Offer Rate (“LIBOR”) plus an applicable rate of 3.50% (or 3.25% if the Senior Secured Net Leverage Ratio, as defined in the 2018 Credit Agreement, is equal to or falls below 4.00 to 1.00) or (ii) the Alternate Base Rate (“ABR”) plus an applicable margin. The Company may elect interest periods of one, two, three or six months for Adjusted LIBOR borrowings. As set forth in the 2018 Credit Agreement, the Alternate Base Rate is the higher of: (i) the rate that Morgan Stanley Senior Funding, Inc. as Administrative Agent announces from time to time as its prime or base commercial lending rate, as in effect from time to time, (ii) the Federal Funds Effective Rate plus ½ of 1.0% and (iii) one-month Adjusted LIBOR plus 1.0%.

The 2018 Term Facility has an original issue discount of 1.5% and the Company incurred approximately $33.0 million in debt issuance costs. The original issue discount and the debt issuance costs will be reported on the balance sheet as adjustments to the carrying amount of the debt liability and will be amortized into interest expense using the effective interest method. Commitment fees related to the 2018 Revolving Facility will be recorded as an asset and amortized over the contractual term.

Interest Rate Swap—To mitigate the risk of a ~~similar amount~~rise in interest rates, the Company entered into multiple interest rate swap transactions during April 2018. These interest rate swaps mitigate the exposure on the variable component of ~~debt.~~interest on the Term Facility discussed above. The transactions fix the LIBOR rate component of interest on $600.0 million of the Term Facility at a

weighted average rate of approximately 2.8%. These interest rate swap transactions are designated as cash flow hedges and are deemed highly effective under ASC 815, Derivatives and Hedging. The interest rate swap transactions will be recorded on the balance sheet at fair value and any changes to the fair value will be recorded through accumulated other comprehensive income and reclassified into interest expense in the same period in which the hedged transaction is recognized in earnings.

Item 2. ~~Management's~~Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q and with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, ~~2016,~~2017, as filed with the Securities and Exchange Commission (the ~~"SEC"~~“SEC”) on February ~~23, 2017~~21, 2018 (the ~~"2016~~“2017 Form ~~10-K"~~10-K”). Unless we otherwise indicate or the context requires, references to the ~~"Company," "Inovalon," "we," "our,"~~“Company,” “Inovalon,” “we,” “our,” and ~~"us"~~“us” refer to Inovalon Holdings, Inc. and its consolidated subsidiaries.

Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the ~~"Securities Act"~~“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the ~~"Exchange Act"~~“Exchange Act”). All statements contained in this Quarterly Report other than statements of historical fact, including but not limited to statements regarding our future results of operations and financial position, our business strategy and plans, market growth, and our objectives for future operations, are forward-looking statements. The words ~~"believe," "may," "see," "will," "estimate," "continue," "anticipate," "intend," "expect,"~~“believe,” “may,” “see,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this Quarterly Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

Factors that may cause actual results to differ from expected results include, among others:

our future financial performance, including our ability to continue and manage our growth;

our ability to retain our client ~~base;~~base and sell additional services to them;

the effect of the concentration of our revenue among our top clients;

our ability to innovate and adapt our platforms and toolsets;

the effects of regulations applicable to us, including regulations relating to data protection and data privacy;

the effects of consolidation in the healthcare industry;

the ability to successfully integrate our acquisitions including CCS and ABILITY and the ability of the acquired business to perform as expected;

the ability to enter into new agreements with existing or new platforms, products, and solutions in the timeframes expected, or at all;

the successful implementation and adoption of new platforms, products and solutions;

the effects of changes in tax legislation for jurisdictions within which we ~~operate;~~operate, including recent changes in U.S. tax laws;

the ability to protect the privacy of our ~~clients'~~clients’ data and prevent security breaches;

the ~~continuation of our share repurchase program;~~

~~the~~ effect of current or future ~~securities class action and other~~ litigation;

the effect of competition on our business; and

the efficacy of our platforms and toolsets.

Forward-looking statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from those anticipated by such statements. These factors include, among other factors, those set forth in our ~~2016~~2017 Form 10-K, under the heading Part I, Item 1A, ~~"Risk~~“Risk Factors."”

You should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or

achievements. We are under no duty to, and we disclaim any obligation to, update any of these forward- looking statements after the date of this Quarterly Report or to conform these statements to actual results or revised expectations.

Overview

We are a leading technology company providing ~~an integrated,~~ cloud-based ~~platform, referred to as the Inovalon ONE™ Platform,~~platforms empowering a data-driven transformation from volume-based to value-based models throughout the healthcare industry. Through the Inovalon ONE™ Platform, Inovalon brings to the marketplace a national-scale capability to interconnect with the healthcare ecosystem on a very large scale, aggregate and analyze data in petabyte volumes to arrive at sophisticated insights in real-time, drive impact wherever it is analytically identified best to intervene, and intuitively visualize data and information to inform business strategy and execution. Leveraging ~~large-scale data interconnectivity~~its platform capabilities, large proprietary data sets, ~~advanced analytics, data-driven intervention systems,~~ and ~~deep~~industry-leading subject matter expertise, ~~we enable~~Inovalon enables the assessment and improvement of clinical and quality outcomes and financial performance across the healthcare ecosystem. From health plans and provider organizations, to pharmaceutical, medical device, and diagnostics companies, ~~our~~Inovalon’s unique achievement of value is delivered through the effective progression of ~~Turning~~“Turning Data into Insight, and Insight into ~~Action® by utilizing the powerful combination of capabilities, flexibility, and performance offered by the Inovalon ONE™ Platform.~~Action^®.” Providing technology ~~and services~~ that ~~support nearly~~supports a client base approaching 500 healthcare organizations, ~~Inovalon's capabilities~~Inovalon’s platforms are informed by data pertaining to more than ~~858,000~~941,000 physicians, ~~377,000~~483,000 clinical facilities, 243 million individuals, and ~~more than approximately 230 million individuals.~~38 billion medical events.

We generate the substantial majority of our revenue through the sale or subscription licensing of our platform solutions and services.

Recent Developments

On April 2, 2018, the Company acquired Butler Group Holdings, Inc., a Delaware corporation and its wholly-owned subsidiaries, including, without limitation, ABILITY Network Inc., a Delaware corporation (“ABILITY”), for aggregate consideration of approximately $1.17 billion in cash and restricted shares of our Class A common stock. The combination of Inovalon and ABILITY creates a vertically integrated cloud-based ~~data analytics, intervention~~platform empowering the achievement of real-time, value-based care from payers, manufacturers, and ~~reporting platforms~~diagnostics all the way to the patient’s point of care. As the acquisition of ABILITY was completed after March 31, 2018, our consolidated financial statements do not include the financial condition or the results of operations of ABILITY in any of the periods presented herein. See “Note 8—Subsequent Events” in the Notes to our unaudited condensed consolidated financial statements included under Part I, Item 1 within this Quarterly Report on Form 10-Q for additional information.

In connection with the ABILITY Acquisition, on April 2, 2018, the Company entered into a credit agreement with Morgan Stanley Senior Funding, Inc., as administrative agent, to provide a Credit Facility which is comprised of: (i) a term loan B facility with the Company as borrower in a total principal amount of $980.0 million; and ~~related support services.~~(ii) a revolving credit facility with the Company as borrower in a total principal amount of up to $100.0 million. See “Note 8—Subsequent Events” in the Notes to our unaudited condensed consolidated financial statements included under Part I, Item 1 within this Quarterly Report on Form 10-Q for additional information.

The Company adopted new accounting guidance on revenue from contracts with customers as of January 1, 2018 using the modified retrospective approach. Revenues for periods beginning after January 1, 2018 are presented under Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under ASC 605. See “Note 2—Revenue” in the Notes to our unaudited condensed consolidated financial statements included under Part I, Item 1 within this Quarterly Report on Form 10-Q for additional information.

Quarterly Key Metrics

We review certain metrics quarterly, including the key metrics shown in the table below. We believe that these metrics are indicative of our overall level of analytical activity and the underlying growth in our business.


	June 30,		March 31,
	2017	2016	2018	2017
	(in thousands)		(in thousands)
MORE² Registry® dataset metrics(1)
MORE² Registry^® dataset metrics⁽¹⁾
Unique patient count~~(5)~~(2)	230,000	137,490	243,421	158,482
Medical event count~~(5)~~(3)	30,000,000	11,755,048	38,792,430	14,016,628
Trailing 12 month Patient Analytics Months (PAM)(1)(4)	31,226,926	24,267,703
Trailing 12 month Patient Analytics Months (PAM)⁽¹⁾⁽⁴⁾			45,171,786	28,303,430

(1)

MORE² ~~Registry®~~Registry^® dataset metrics and Trailing 12 month PAM, each of which is presented in the table, are key operating metrics that management uses to assess our level of operational activity. While we believe that each of these metrics is indicative of our overall level of analytical activity and the underlying growth in our business, increases or decreases in these metrics do not necessarily correlate to proportional increases or decreases in revenue, or net income. For instance, although increased levels of analytical activity historically have corresponded to increases in revenue over the long term, differences in fees charged for different analytical packages exist and differences in how analytics trigger the applicability of our data-driven intervention platforms may result in increases in analytical activity that do not result in proportional increases in revenue, or net income (and vice versa). Accordingly, while we believe the presentation of these operating metrics is helpful to investors in understanding our business, these metrics have limitations and should not be considered as substitutes for analysis of our financial results reported under generally accepted accounting principles ("GAAP"). In addition, we believe that other companies, including companies in our industry, do not present similar operating metrics and that there is no commonly accepted method of calculating these metrics, which may reduce their usefulness as comparative measures.

levels of analytical activity historically have corresponded to increases in revenue over the long term, differences in fees charged for different analytical packages exist and differences in how analytics trigger the applicability of our data-driven intervention platforms may result in increases in analytical activity that do not result in proportional increases in revenue, or net income (and vice versa). Accordingly, while we believe the presentation of these operating metrics is helpful to investors in understanding our business, these metrics have limitations and should not be considered as substitutes for analysis of our financial results reported under generally accepted accounting principles (“GAAP”). In addition, we believe that other companies, including companies in our industry, do not present similar operating metrics and that there is no commonly accepted method of calculating these metrics, which may reduce their usefulness as comparative measures.


(2)	Unique patient count is defined as each unique, longitudinally matched, de-identified natural person represented in our MORE² ~~Registry®~~Registry^® as of the end of the period presented.


(3)	Medical event count is defined as the total number of discrete medical events as of the end of the period presented (for example, a discrete medical event typically results from the presentation of a patient to a physician for the diagnosis of diabetes and congestive heart failure in a single visit, the presentation of a patient to an emergency department for chest pain, etc.).

(4)

PAM is defined as the sum of the analytical processes performed on each respective patient within patient populations covered by clients under contract. As used in the metric, an ~~"analytical process"~~“analytical process” is a distinct set of data calculations undertaken by us which is initiated and completed bywithin our ~~analytical~~ platform solutions to examine a specific question such as whether a patient is believed to have a condition such as diabetes, or worsening of the disease, during a specific time period.


~~(5)~~	As of June 30, 2017, the Company was processing large unique patient count and medical event count dataset transmissions. For this reason, the determination of the June 30, 2017 unique patient count and medical event count amounts vary from historical calculation methodologies, and represent estimates pending final MORE² ~~Registry® dataset incorporation and processing.~~

Trends and Factors Affecting Our Future Performance

A number of factors influence our growth and performance. We see many of these factors as being more quantitatively driven, such as the rate of growth of the underlying data counts within our datasets, the ongoing investment in innovation, ~~the number of statement of work contracts maintained by us,~~ and our ~~level~~revenue mix of ~~analytical activity.~~subscription-based platform offerings. Additionally, there are several factors that influence our growth and performance that are less quantitatively driven, including seasonality, macro-economic forces, and trends within healthcare (such as payment models, incentivization, and regulatory oversight), that can be driven by changes in federal and state laws and regulations, as well as private sector market forces.

Growth of Datasets. Healthcare costs in the United States have been increasing significantly for many years. This rise in healthcare costs has driven a broad transition from consumption-based payment models to quality and value-based payment models across the healthcare landscape. As a result, the specific disease and comorbidity status, clinical and quality outcomes, resource utilization, and care details of the individual patient have become increasingly relevant to the various constituents across the healthcare delivery system. Concurrently, the count and complexity of diseases, diagnostics, and ~~treatments~~—treatments—as well as payment models and regulatory oversight ~~requirements~~—requirements—have soared. In this setting, granular data has become critical to determining and improving quality and financial performance in healthcare. Our MORE² ~~Registry®~~Registry^® is our largest principal dataset and serves as a proxy for our general growth of datasets within Inovalon. The growth of our datasets that inform our analytical capabilities and comparative analytics is a key aspect of our provision of value to our clients and is indicative of our overall growth and capabilities.

Innovation and Platform Development. Our business model is based upon our ability to deliver value to our clients through ~~the combination of advanced, cloud-based data analytics~~our platform solutions and ~~data-driven intervention platforms~~related services focused on the achievement of meaningful and measurable improvements in clinical quality outcomes and financial performance in healthcare. Our ability to deliver this value is dependent in part on our ability to continue to innovate, design new capabilities, enter into new agreements with clients for new platforms, and bring these capabilities to market in an enterprise scale. Our continued ability to innovate our platform and bring differentiated capabilities to market is an important aspect of our business success.

Our investment in innovation includes costs for research and development, capitalized software development, and capital expenditures related to hardware and software platforms on which our ~~data analytics and data-driven interventions capabilities~~platform solutions are deployed as summarized below (in thousands, except percentages).


	Three Months Ended June 30,						Six Months Ended June 30,						Three Months Ended March 31,
	2017			2016			2017			2016			2018			2017
Investment in Innovation:
Research and development(1)	$	7,282		$	7,711		$	15,070		$	13,643
Capitalized software development(2)	8,793			6,232			14,933			11,532
Research and development infrastructure investments(3)	5,828			2,600			9,586			2,979
Research and development⁽¹⁾													$	6,421		$	7,788
Capitalized software development⁽²⁾													10,296			6,140
Research and development infrastructure investments⁽³⁾													8,765			3,758
Total investment in innovation	$	21,903		$	16,543		$	39,589		$	28,154		$	25,482		$	17,686
As a percentage of revenue
Research and development(1)	7		%	6		%	7		%	6		%
Capitalized software development(2)	8		%	5		%	7		%	5		%
Research and development infrastructure investments(3)	5		%	2		%	4		%	1		%
Research and development⁽¹⁾													7		%	7		%
Capitalized software development⁽²⁾													11		%	6		%
Research and development infrastructure investments⁽³⁾													9		%	3		%
Total investment in innovation	20		%	13		%	18		%	12		%	27		%	16		%


(1)	Research and development primarily includes employee costs related to the development and enhancement of our service offerings.


(2)	Capitalized software development includes capitalized costs incurred to develop and enhance functionality for our ~~data analytics and data-driven intervention platforms.~~platform solutions.


(3)	Research and development infrastructure investments include strategic capital expenditures related to hardware and software platforms under development or enhancement.

~~Data Analytics~~Mix of Subscription-Based Platform Offerings and ~~Data-Driven Intervention Mix.~~Legacy Solutions. ~~Our business~~We have been undergoing an intentional transition in our offering portfolio from legacy platform solutions to subscription-based cloud-based platform offerings with add-on advisory services. Subscription-based cloud-based platform offerings are generally defined as modular, cloud-based solutions that utilize dynamic, high-speed cloud-based compute and ~~operational models~~storage, offer enhanced data visualization capabilities, and are ~~highly scalable and leverage variable costs~~tied to ~~support~~subscription-based contract structures where revenue ~~generating activities. Our data analytic service costs~~is predominantly based on factors such as the number of patients under contract or similar relevant metrics (e.g., the number of prescriptions issued), the size of the client, and/or a specific period of time. Legacy platform solutions are ~~less variable~~generally defined as solutions historically not cloud-based in nature and ~~require lower incremental capital expenditures.~~not tied to subscription-based contract structures. Over time, we believe subscription-based cloud-based platform offerings provide more advanced capabilities, higher value, and greater visibility to clients, as well as improved visibility, market differentiation, and financial performance for us.

Breadth of Healthcare Industry Connectivity. The healthcare industry is undergoing a significant transition from volume-based to value-based care and payment models. As ~~a result, following initial development~~part of this transition, participants across the healthcare industry, including health plans, pharmaceutical companies, medical device manufacturers, and ~~deployment investments,~~diagnostic companies, are increasingly interested in achieving timely and seamless access to relevant data and being able to drive impact directly with providers and their patients. Concurrently, providers are also increasingly interested in access to more advanced analytical tools to support and improve their performance under value-based care arrangements. Enhancing and expanding our ~~big data analytics platform~~industry connectivity with payer administrative systems, provider facilities, diagnostic systems, pharmacy systems, healthcare industry systems (e.g., electronic healthcare record systems, health information exchange systems, claims processing systems, decision support systems, etc.), and ~~data technology capabilities allow us to process significant volumes of transactions with lower incremental costs. Conversely, our data-driven intervention costs are generally variable~~other healthcare clinical and business systems, offers the potential for increased differentiation in ~~nature and require incremental costs to generate additional revenue. As a result,~~ the ~~mix~~healthcare marketplace as well as improved efficiency of our ~~data analytics and data interventions activities affects our financial performance.~~operations.

Client and Analytical Process Count Growth. Our business is generally driven by the number of underlying patients for which our ~~analytics and data-driven intervention platforms~~platform solutions are being utilized. As such, we track the number of analytical processes that we run on patients each month in fulfillment of our client contracts, as totaled for the trailing 12 months. ~~This metric is referred to as the Trailing 12 month Patient Analytical Months, or PAM.~~ We believe that PAM is indicative of our overall level of analytical activity, and we expect our period-to-period comparisons of our PAM to be indicative of underlying growth of our business, although changes in levels of analytical activity do not always directly translate to changes in financial performance of our business. Differences in fees charged for different analytical packages exist and differences in how analytics trigger the applicability of our data-driven intervention platforms may result in increases in analytical activity that do not result in proportional increases in revenue, or net income (and vice versa). Therefore, in situations in which a new engagement is initiated for analytical processes that have a higher than average fee rate, revenue could expand disproportionately faster than the increase in PAM. Likewise, if engagements for analytical processes that have a higher than average fee rate are concluded then such conclusions can negatively affect revenue disproportionately more than PAM.

Seasonality. The nature of our ~~customers'~~customers’ end-market results in partial seasonality reflected in both revenue and cost of revenue differences during the year. Regulatory impact of data submission deadlines in, for example, January, March, June, and September ~~and January~~ drive some degree of predictable timing of analytics and data processing activity variances from quarter to quarter. Further, regulatory clinical encounter deadlines of June 30th and December 31st drive predictable intervention concentrations

variances from quarter to quarter. The timing of these factors results in analytical and intervention activity mix variances which ~~predictably~~have limited predictable impact in the aggregate on our financial performance from quarter to quarter. ~~Finally,~~However, quarter to quarter financial performance may increasingly vary from historical seasonal trends as we ~~further~~continue to expand into adjacent markets and increase the portion of our revenue generated from new offerings. Further, we also expect the impact of seasonality to decrease over time as we expand our mix of revenue generated from a subscription-based model.

Regulatory, Economic and Industry Trends. Our clients are affected, sometimes directly and sometimes counter-intuitively, by macro-economic trends such as economic growth (or economic recession), inflation, and unemployment. Further, industry trends in federal and state laws and regulations, as well as emerging trends in private sector payment models, affect our ~~clients'~~clients’ businesses and their need for technologies and services to support these challenges. These factors have various effects on our business, and on occasion have resulted in the slowing or cessation of the decision-making process by clients adopting our technologies and services. On the other hand, changes in macro-economic trends and the industry landscape have accelerated the need for our technologies and services from time-to-time, particularly as regulators introduce complex requirements with which our clients must comply.

~~Shift to Fully Automated Data-Driven Intervention Platform Services.~~ We view the decreased proportion of revenue derived from partially automated data-driven intervention platform services as a positive reflection of our cloud-based interconnectivity and automation capabilities. The proportion of our revenue derived from pure data analytics and fully automated data-driven intervention platform services revenue is expected to continue to expand over time as a percentage of total revenue as a result of our continued expansion of our cloud-based interconnectivity technologies and the continued expansion of interconnectivity within the healthcare landscape. In order to drive value for our clients and serve them irrespective of their level of connectivity, we continue to provide cloud-based partially automated data-driven intervention platform services, converting the performance of such services to cloud-based fully automated data-driven intervention platform services wherever possible. As the healthcare infrastructure becomes more interconnected and our integration and interconnectivity technologies continue to expand, we believe that we will be able to achieve more rapid implementation, and greater value impact, at more efficient costs.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with GAAP. In connection with the preparation of our unaudited condensed consolidated financial statements, we are required to make assumptions and estimates about future events, and apply judgments that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. We base our assumptions, estimates, and judgments on historical experience, current trends, and other factors we believe to be relevant at the time we prepare our unaudited condensed consolidated financial statements. The accounting estimates used in the preparation of our unaudited condensed consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained, and as our operating environment changes. On a

regular basis, we review the accounting policies, assumptions, and evaluate and update our assumptions, estimates, and judgments to ensure that our unaudited condensed consolidated financial statements are presented fairly and in accordance with GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material.

Critical accounting policies are those policies that affect our more significant judgments and estimates used in the preparation of our unaudited condensed consolidated financial statements. For a more detailed discussion of our critical accounting policies, please refer to our ~~2016~~2017 Form 10-K.

Components of Results of Operations

Revenue

We earn revenue primarily through the sale or subscription licensing of our platform solutions and arrangements for advisory, implementation, and support services.

Platform solutions include arrangements for technology-based offerings representing subscription-based cloud-based ~~data analytics, data-driven intervention~~ platform ~~services, our advisory services~~offerings and ~~business intelligence solutions.~~

legacy platform solutions that are not cloud-based and not billed under a subscription-based contract structure. Our cloud-based data analytics services are performed either at the beginning of a data-driven intervention process, which typically aligns with regulatory submission deadlines, or on a monthly basis, depending on the particular client's needs. Cloud-based data analyticsplatform solutions revenue is driven primarily by cloud-based data connectivity, analytics, intervention, and visualization software that enables the ~~number~~identification and resolution of ~~identified~~ gaps in care, quality, ~~data integrity,~~utilization, compliance, and/or other gaps that may impact our clients’ achievement of greater healthcare quality and financial performance identified in a client's dataset, the number of unique patients in a client's dataset, a minimum data analytics processing fee, and a contractually negotiated transactional price for each identified gap or unique patient. Subscription licensing revenueassociated with value-based care. Revenue is ~~driven primarily by~~predominantly based on the number of clients, the number of ~~unique~~ patients ~~in a client's population dataset,~~or similar relevant metrics (e.g., the number of prescriptions issued), the size of the client, the number of analytical services contracted for by a client and the contractually negotiated price of such services.

~~Cloud-based data-driven intervention platform service~~ Additionally, revenue ~~represents revenue that~~ is generated from fully automated processes (i.e., those processes that require no material variable-based labor components) and partially automated processes (i.e., those processes that require a degreebased on the number of ~~variable-based labor components). As many of our analytical capabilities are designed to identify~~identified and/or resolved gaps in care, quality, utilization, compliance, and/or other gaps that may impact our clients' achievement of greater healthcare quality and financial performance, our cloud-based data driven intervention platform services revenue is driven primarily by the results of our cloud-based data analytics processes and our clients' desire to utilize our cloud-based data-driven intervention platforms to resolve such identified gaps. Informed by our analytics, our cloud-based data-driven intervention platforms are designed to enable the resolution of specific gaps through the aggregation of specific data or achievement of specific impact. Revenueresulting from our ~~intervention platform utilization is generally driven by the quantity and type of completed interventions enabled by our platform, and~~analytical services at a contractually negotiated transactional price for each ~~such intervention.~~identified and/or resolved gap.

~~Advisory service~~The majority of our platform solutions contracts contain a series of separately identifiable and ~~business intelligence~~distinct services that represent performance obligations that are satisfied over time. Revenue is allocated to platform solutions by determining the standalone selling price of each performance obligation. Revenue is generally recognized on our platform offerings over the contract term. For certain contracts, we have determined that we will recognize revenue when we have the right to invoice.

Service revenue represents revenue that is generated from strategic advisory, ~~analysis~~implementation and ~~educational~~support services. Revenue from our ~~advisory~~ services arrangements is generally provided under time and materials, fixed-price, or retainer-based contracts, based on ~~contractually negotiated prices for each such arrangement.~~agreed upon billing rates applied to direct labor hours expended plus the costs of other items used in the performance of the contract. We recognize revenue when we have the right to invoice the customer using the allowable practical expedient since the right to invoice the customer corresponds with the performance obligations completed. Revenues under fixed-price and retainer-based contracts are recognized ratably over the contract period or upon contract completion.

Cost of Revenue

Cost of revenue consists primarily of expenses for employees who provide direct contractual services to our clients, including salaries, benefits, discretionary incentive compensation, employment taxes, severance, and equity compensation costs. Cost of revenue also includes expenses associated with the integration, and verification of data and other service costs incurred to fulfill our revenue contracts. Cost of revenue does not include allocated amounts for occupancy expense and depreciation and amortization. Many of the elements of our cost of revenue are relatively variable and semi-variable, and can be reduced in the near-term to help offset any decline in our revenue.

Our business and operational models are designed to be highly scalable and leverage variable costs to support revenue generating activities. While we ~~expect to~~may grow our headcount over time to capitalize on our market opportunities, we believe our increased investment in automation, electronic health record integration capabilities, and economies of scale in our operating model, will position us to grow our ~~cloud-based data analytics and cloud-based data-driven intervention~~ platform ~~services~~solutions revenue at a greater rate than our cost of revenue, over time, excluding the impact of stock-based compensation expense.

Sales and Marketing

Sales and marketing expense consists primarily of employee-related expenses, including salaries, benefits, commissions, discretionary incentive compensation, employment taxes, severance, and equity compensation costs for our employees engaged in sales, sales support, business development, and marketing. Sales and marketing expense also includes operating expenses for marketing programs, research, trade shows and brand messages, and public relations costs. Our sales and marketing expense excludes any allocation of occupancy expense and depreciation and amortization.

We expect our sales and marketing expenses to continue to increase in absolute dollar terms as we strategically invest to expand our ~~business. We expect~~business, although it may vary from period to hire additional sales personnel and related support personnel to capture an increasing amount of our market opportunity. As we scale our sales and marketing activities in the short to medium term, we expect these expenses to increase in both absolute dollars andperiod as a percentage of ~~revenue.~~total revenues.

Research and Development

Research and development expense (one component of our investment in innovation) consists primarily of employee-related expenses, including salaries, benefits, discretionary incentive compensation, employment taxes, severance, and equity compensation costs for our software developers, engineers, analysts, project managers, and other employees engaged in the development and enhancement of our service offerings. Research and development expense also includes certain third party consulting fees. Our research and development expense excludes any allocation of occupancy expense and depreciation and amortization.

We expect to continue our focus on developing new product offerings and enhancing our existing product offerings. As a result, we expect our research and development expense to increase in absolute dollars, although it may vary from period to period as a percentage of ~~revenue.~~revenue.

General and Administrative

Our general and administrative expense consists primarily of employee-related expenses including salaries, benefits, discretionary incentive compensation, employment taxes, severance, and equity compensation costs, for employees who are responsible for management information systems, administration, human resources, finance, legal, and executive management. General and administrative expense also includes occupancy expenses (including rent, utilities, communications, and facilities maintenance), professional fees, consulting fees, insurance, travel, and other expenses. Our general and administrative expense excludes depreciation and amortization.

We expect our general and administrative expense to increase in absolute dollars and as a percentage of revenue driven by certain one-time costs including the expansion of our business ~~and increases in stock-based compensation expense. However,~~through acquisitions. Over the long term, we expect general and administrative expense to decrease as a percentage of ~~revenue, to decrease over time.~~revenue.

Depreciation and Amortization Expense

Our depreciation and amortization expense consists primarily of depreciation of fixed assets, amortization of capitalized software development costs, and amortization of acquisition-related intangible assets.

We expect our depreciation and amortization expense to increase as we expand our business organically and through acquisitions.

Realized Losses on Short-term Investments

Realized losses on short-term investments consist of losses realized upon the sale of certain of the Company’s available-for-sale securities, prior to their maturity. The losses were incurred as the value of the available-for-sale securities declined from the date of purchase to the date of sale.

We expect to incur realized gains or losses to the extent the available-for-sale securities are sold prior to their maturity. From time to time we may sell our available-for-sale securities prior to their maturity to generate cash needed to fund strategic initiatives including acquisitions.

(Loss) Gain on Disposal of Equipment

Gain on disposal of equipment consists of proceeds received for the disposition of equipment that were greater than the equipment’s depreciated book value.

We expect to recognize gains on disposal of equipment to the extent that proceeds received upon disposal are greater than the carrying value of the underlying equipment, otherwise loss on disposal of equipment could be incurred.

Interest Income

Interest income represents interest earned net of amortization of premium for purchased interest from our available-for-sale short-term investments.

We expect our interest income to fluctuate in proportion to the amount of funds we invest, according to our corporate investment policy, in available-for-sale short-term investments and considering prevailing available interest rate yields on such investment grade debt securities.

Interest Expense

Interest expense represents interest incurred on our Credit Facilities (as defined below, under the heading ~~"Liquidity~~“Liquidity and Capital Resources—~~Debt"~~Debt”).

We expect our interest expense to increase in connection with the debt commitment discussed in Note 8, “Subsequent Event” and to fluctuate in proportion to the outstanding principal balance ~~of the Credit Facilities~~ and the prevailing ~~LIBOR~~London Interbank Offer Rate (“LIBOR”) interest rate.

Provision for Income Taxes

Provision for income taxes consists of federal and state income taxes in the United States and foreign income taxes from the territory of Puerto Rico, including deferred income taxes reflecting the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and excess tax benefits or deficiencies derived from exercises of stock options and vesting of restricted stock.

We expect that our effective tax rate will decrease due to the Tax Act, which was signed into law on December 22, 2017 and is effective January 1, 2018, and in the future may fluctuate due to the recognition of excess tax benefits and tax deficiencies associated with ~~adopting ASU 2016-09,~~ ~~Compensation-Stock Compensation (Topic 718): Improvements~~stock-based compensation transactions which are considered to ~~Employee Share-Based Payment Accounting~~.be discrete items. Excluding discrete items impacting the effective tax rate, we ~~are expecting~~expect our long-term tax rate to reflect the applicable statutory rates.

RESULTS OF OPERATIONS

The following table sets forth our consolidated statement of operations data for each of the periods presented (in thousands, except percentages):


	Three Months Ended June 30,						Change from 2016 to 2017					Six Months Ended June 30,						Change from 2016 to 2017					Three Months Ended March 31,						Change from 2017 to 2018
	2017			2016			$			%		2017			2016			$			%		2018			2017			$			%
Revenue	$	110,578		$	123,825		$	(13,247	)	(11	)%	$	218,884		$	226,482		$	(7,598	)	(3	)%	$	92,755		$	108,306		$	(15,551	)	(14	)%
Expenses:
Cost of revenue(1)	37,198			43,214			(6,016		)	(14	)%	75,483			85,137			(9,654		)	(11	)%
Sales and marketing(1)	8,849			6,116			2,733			45	%	16,436			12,675			3,761			30	%
Research and development(1)	7,282			7,711			(429		)	(6	)%	15,070			13,643			1,427			10	%
General and administrative(1)	35,874			31,461			4,413			14	%	71,719			68,013			3,706			5	%
Cost of revenue⁽¹⁾																							33,491			38,285			(4,794		)	(13	)%
Sales and marketing⁽¹⁾																							7,902			7,587			315			4	%
Research and development⁽¹⁾																							6,421			7,788			(1,367		)	(18	)%
General and administrative⁽¹⁾																							49,396			35,845			13,551			38	%
Depreciation and amortization	12,479			8,496			3,983			47	%	24,964			16,890			8,074			48	%	16,380			12,485			3,895			31	%
Total operating expenses	101,682			96,998			4,684			5	%	203,672			196,358			7,314			4	%	113,590			101,990			11,600			11	%
Income from operations	8,896			26,827			(17,931		)	(67	)%	15,212			30,124			(14,912		)	(50	)%
(Loss) Income from operations																							(20,835		)	6,316			(27,151		)	(430	)%
Other income and (expenses):
Realized losses on short-term investments	—			(1		)	*			*%		—			(5		)	*			*%		(1,035		)	—			*			*%
(Loss) Gain on disposal of equipment	(138		)	—			*			*%		(138		)	534			*			*%
Loss on disposal of equipment																							(85		)	—			*			*%
Interest income	1,342			1,532			(190		)	(12	)%	2,680			2,974			(294		)	(10	)%	1,395			1,338			57			4	%
Interest expense	(1,519		)	(1,245		)	(274		)	22	%	(2,932		)	(2,504		)	(428		)	17	%	(1,882		)	(1,413		)	(469		)	33	%
Income before taxes	8,581			27,113			(18,532		)	(68	)%	14,822			31,123			(16,301		)	(52	)%
Provision for income taxes	3,095			10,862			(7,767		)	(72	)%	5,694			12,507			(6,813		)	(54	)%
Net income	$	5,486		$	16,251		$	(10,765	)	(66	)%	$	9,128		$	18,616		$	(9,488	)	(51	)%
(Loss) Income before taxes																							(22,442		)	6,241			(28,683		)	(460	)%
(Benefit from) Provision for income taxes																							(5,608		)	2,599			(8,207		)	(316	)%
Net (loss) income																							$	(16,834	)	$	3,642		$	(20,476	)	(562	)%

(1) Includes stock-based compensation expense as follows:
Cost of revenue $ 410
$ 121
$ 289
239 % $ 715
$ 240
$ 475
198 %
Sales and marketing 505
152
353
232 % 895
306
589
192 %
Research and development 307
499
(192 ) (38 )% 580
741
(161 ) (22 )%
General and administrative 2,525
1,364
1,161
85 % 5,154
2,941
2,213
75 %
Total stock-based compensation expense $ 3,747
$ 2,136
$ 1,611
75 % $ 7,344
$ 4,228
$ 3,116
74 %



(1)	Includes stock-based compensation expense as follows:
	Cost of revenue	$	140	$	305	$	(165	)	(54	)%
	Sales and marketing	469		390		79			20	%
	Research and development	628		273		355			130	%
	General and administrative	2,511		2,629		(118		)	(4	)%
	Total stock-based compensation expense	$	3,748	$	3,597	$	151		4	%

* Asterisk denotes not meaningful.

The following table sets forth our consolidated statement of operations data for each of the periods presented as a percentage of revenue:


	Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended March 31,
	2017		2016		2017		2016		2018		2017
Revenue	100	%	100	%	100	%	100	%	100	%	100	%
Expenses:
Cost of revenue	34	%	35	%	34	%	38	%	36	%	35	%
Sales and marketing	8	%	5	%	8	%	6	%	9	%	7	%
Research and development	7	%	6	%	7	%	6	%	7	%	7	%
General and administrative	32	%	25	%	33	%	30	%	53	%	33	%
Depreciation and amortization	11	%	7	%	11	%	7	%	18	%	12	%
Total operating expenses	92	%	78	%	93	%	87	%	123	%	94	%
Income from operations	8	%	22	%	7	%	13	%
(Loss) Income from operations									(23	)%	6	%
Other income and (expenses):
Realized losses on short-term investments	—	%	—	%	—	%	—	%	(1	)%	—	%
(Loss) Gain on disposal of equipment	—	%	—	%	—	%	—	%
Loss on disposal of equipment									*%		—	%
Interest income	1	%	1	%	1	%	1	%	2	%	1	%
Interest expense	(1	)%	(1	)%	(1	)%	(1	)%	(2	)%	(1	)%
Income before taxes	8	%	22	%	7	%	13	%
Provision for income taxes	3	%	9	%	3	%	5	%
Net income	5	%	13	%	4	%	8	%
(Loss) Income before taxes									(24	)%	6	%
(Benefit from) Provision for income taxes									(6	)%	2	%
Net (loss) income									(18	)%	4	%

* Asterisk denotes not meaningful.

Comparison of the Three ~~and Six~~ Months Ended ~~June 30,~~March 31, 2018 and 2017 ~~and 2016~~

Revenue

~~During~~Revenue for the three months ended ~~June 30, 2017,~~March 31, 2018 was $92.8 million, a decrease of 14% compared with revenue ~~decreased by approximately $13.2~~of $108.3 million ~~or 11%, compared with~~for the three months ended ~~June 30, 2016. The~~March 31, 2017. This decrease was primarily attributable to a ~~net~~ decrease of ~~approximately $23.7~~$22.1 million in revenue from existing clients resulting from a combination of factors including decisions by a limited number of clients to withdraw from Affordable Care Act (as amended by the Health Care and Education Reconciliation Act of 2010) markets, the transition of client contracts to newer product offerings and more subscription-based agreements versus the year-ago period, and the conclusion of client contracts included in the year-ago period, which was partially offset by an increase of $4.7 million in revenue contributed from new clients ~~of approximately $10.5 million.~~

During the six months ended June 30, 2017, revenue decreased by approximately $7.6 million, or 3%, compared with the six months ended June 30, 2016. The decrease was primarily attributable to a net decrease of approximately $30.1signed and $1.9 million in revenue from ~~existing clients, partially offset by an increase in revenue from new clients~~the acquired business of ~~approximately $22.5 million.~~CCS.

Cost of Revenue

During the three months ended ~~June 30, 2017,~~March 31, 2018, cost of revenue decreased by ~~approximately $6.0~~$4.8 million, or ~~14%~~13%, compared with the three months ended ~~June 30, 2016.~~March 31, 2017. The decrease in cost of revenue was primarily attributable to a decrease of employee-related expenses of $4.5 million driven by technology-enabled platform efficiency initiatives, a decrease in professional third-party costs of $1.8 million, and a decrease in fulfillment of $0.6 million, which was partially offset by the ~~composition~~incremental cost of ~~a greater volume~~revenue of ~~data-driven analytics as a percentage~~$2.2 million attributable to the acquired business of ~~revenue.~~CCS. Cost of revenue as a percentage of revenue was ~~34%~~36% and 35% for the three months ended ~~June 30,~~March 31, 2018 and 2017, ~~and 2016, respectively.~~

During the six months ended June 30, 2017, cost of revenue decreased by approximately $9.7 million, or 11%, compared with the six months ended June 30, 2016. The decrease in cost of revenue was primarily attributable to technology-enabled platform efficiency initiatives and the composition of a greater volume of data-driven analytics as a percentage of revenue. Cost of revenue as a percentage of revenue was 34% and 38% for the six months ended June 30, 2017 and 2016, respectively.

Sales and Marketing

During the three months ended ~~June 30, 2017,~~March 31, 2018, sales and marketing expenses increased by ~~approximately $2.7~~$0.3 million, or ~~45%~~4%, compared with the three months ended June 30, 2016. During the six months ended June 30, 2017, sales and marketing expenses increased by approximately $3.8 million, or 30%, compared with the six months ended June 30, 2016. These increases were primarily attributable to our investment in the growth of our sales team, related sales infrastructure tools, and marketing programs.March 31, 2017. The ~~growth of our sales and marketing team~~increase was driven by our investment ~~in new~~to expand our sales ~~personnel~~organization and partner team to focus on adding new clients and capturing an increased amount of market opportunity.

Sales and marketing expenses as a percentage of revenue was 9% and 7% for the three months ended March 31, 2018 and 2017, respectively.

Research and Development

During the three months ended ~~June 30, 2017,~~March 31, 2018, research and development expense decreased by ~~approximately $0.4~~$1.4 million, or 6%18%, compared with the three months ended ~~June 30, 2016.~~March 31, 2017. The decrease was primarily attributable to an increased ~~emphasis~~focus on ~~enhanced functionality and additional~~ development of ~~the Company's platforms including~~ the Inovalon ONE™ Platform, resulting in an increase to capitalized software ~~projects.~~

~~During the six months ended June 30, 2017, research and development expense increased by approximately $1.4~~projects of $2.6 million, or 10%, compared with the six months ended June 30, 2016. The increase was primarily attributable to incremental growth in employee-related expenses necessary to support our on-going investment in innovation and platform development compared to the prior period, which was partially offset by ~~enhanced functionality and additional development of the Company's platforms including the Inovalon ONE™ Platform, resulting in~~ an increase in professional third-party costs of $0.5 million and incremental expense of $0.3 million attributable to ~~capitalized software projects.~~the acquired business of CCS.

General and Administrative

During the three months ended ~~June 30, 2017,~~March 31, 2018, general and administrative expenses increased by ~~approximately $4.4~~$13.6 million, or ~~14%~~38%, compared with the three months ended ~~June 30, 2016.~~March 31, 2017. The increase was primarily attributable to an increase in employee-related expenses of $4.5 million, which includes an increase in severance expense of $0.7 million related to cost reduction initiatives, incremental expenses of ~~$2.4~~$4.4 million attributable to the ~~acquisition~~acquired business of ~~Creehan and an increase of $1.2 million~~CCS, transaction costs related ~~to stock-based compensation.~~

During the six months ended June 30, 2017, general and administrative expenses increased by approximately $3.7 million, or 5%, compared with the six months ended June 30, 2016. The increase was primarily attributable to incremental expenses of $5.2 million attributable to the acquisition of ~~Creehan,~~ABILITY of $3.0 million, and an increase in professional third-party party costs of ~~$2.2~~$2.5 million, which includes a $1.4 million increase in legal expenses related to ~~stock-based compensation, partially offset by~~non-recurring litigation. General and administrative expenses as a ~~decline in payroll related expenses attributable to our initiative to streamline administrative infrastructure.~~percentage of revenue was 53% and 33% for the three months ended March 31, 2018 and 2017, respectively.

Depreciation and Amortization

During the three months ended ~~June 30, 2017,~~March 31, 2018, depreciation and amortization expense increased by ~~approximately $4.0~~$3.9 million, or ~~47%~~31%, compared with the three months ended ~~June 30, 2016.~~March 31, 2017. The increase was primarily attributable to ~~approximately $0.8~~depreciation of software licenses and computers of $2.3 million, $1.2 million of incremental amortization of capitalized software, $0.1 million of depreciation of other assets related to the acquired businesses of CCS, and ~~$1.9~~$0.1 million of amortization of acquired intangible ~~assets related to the acquisition of Creehan.~~assets.

During the six months ended June 30, 2017, depreciation and amortization expense increased by approximately $8.1 million, or 48%, compared with the six months ended June 30, 2016. The increase was primarily attributable to approximately $2.1 million of incremental amortization of capitalized software, and $3.9 million of amortization of intangible assets related to the acquisition of Creehan.

~~(Loss) Gain~~Loss on Disposal of Equipment

During the three months ended ~~June 30, 2017,~~March 31, 2018, we incurred a loss of $0.1 million related to the disposal of equipment. During the three months ended ~~June 30, 2016,~~March 31, 2017, there were no equipment disposals.

During the six months ended June 30, 2017, we incurred a loss of $0.1 million related to the disposal of equipment. During the six months ended June 30, 2016, we replaced certain data-center equipment. The replacement of the equipment was covered under our insurance and the cost of our replacement equipment was reimbursed by our insurance carrier. As a result, the disposal and replacement of the equipment resulted in a gain of $0.5 million during the six months ended June 30, 2016.

Interest Income

During the three months ended ~~June 30, 2017,~~March 31, 2018, interest income ~~decreased~~increased by ~~approximately $0.2~~$0.1 million, compared with the three months ended June 30, 2016. During the six months ended June 30, 2017, interest income decreased by approximately $0.3 million, compared with the six months ended June 30, 2016. A portion of our available-for-sale short-term investments have been used to fund strategic initiatives such as the acquisition of Creehan and the share repurchase program.March 31, 2017. The ~~decrease~~increase in our interest income was primarily attributable to ~~the decline in~~ the overall value of our available-for-sale short term investment portfolios that resulted in ~~a decrease~~an increase in earnings derived from our available-for-sale short-term investments.

Interest Expense

During the three months ended ~~June 30, 2017,~~March 31, 2018, interest expense increased by ~~approximately $0.3~~$0.5 million, compared with the three months ended ~~June 30, 2016. During the six months ended June 30, 2017, interest expense increased by approximately $0.4 million, compared with the six months ended June 30, 2016.~~March 31, 2017. The increase in interest expense was primarily attributable to an increase in the interest rate on our 2014 Term Loan Facility (as defined below under the heading ~~"Liquidity~~“Liquidity and Capital Resources—~~Debt"~~Debt”) which iswas variable and fluctuates alongside changes to LIBOR.

Provision for Income Taxes

During the three months ended ~~June 30, 2017,~~March 31, 2018, the benefit from income taxes was $5.6 million compared to provision for income taxes ~~decreased by approximately $7.8~~of $2.6 million ~~or 72%, compared to~~for the three months ended June 30, 2016. During the six months ended June 30, 2017, provision for income taxes decreased by approximately $6.8 million, or 54%, compared to the six months ended June 30, 2016. The decrease in income taxes was primarily attributable to a decrease in income before taxes.

March 31, 2017. Our effective tax rate for the three months ended ~~June 30, 2017~~March 31, 2018 was approximately ~~36.1%~~25.0%, as compared towith approximately ~~40.1%~~41.6% for the three months ended ~~June 30, 2016. Our effective tax rate for the six months ended June 30, 2017 was approximately 38.4%, as compared to approximately 40.2% for the six months ended June 30, 2016.~~March 31, 2017. The decrease in our effective tax rate is primarily a result of the Tax Act, which was ~~primarily attributable to excess tax benefit related to equity events.~~signed into law on December 22, 2017 and was effective January 1, 2018.

Liquidity and Capital Resources

Sources of Liquidity

Our principal sources of liquidity have been cash generated by operating activities, proceeds from our initial public offering and proceeds from our Credit Facilities. Our cash generated from such ~~means~~sources has been sufficient to fund our growth, including our capital expenditures. As of ~~June 30, 2017,~~March 31, 2018, our cash, cash equivalents and short-term investments totaled ~~$531.5~~$450.3 million, of which ~~$339.5~~$40.3 million represented short-term, available-for-sale, investment grade, domestic debt-securities, compared ~~to $743.9~~with $533.3 million of cash, cash equivalents, and short-term investments as of ~~June 30, 2016,~~March 31, 2017, of which ~~$584.1~~$385.4 million represented short-term, available-for-sale, investment grade, domestic debt-securities.

We believe our current cash, cash equivalents, and short-term investments balance, expected cash generated by operating activities and availability of cash under our Credit ~~Facilities~~Agreements are sufficient to fund our operations, finance our strategic initiatives, and fund our investment in innovation and new service offerings, ~~and fund our share repurchase program,~~ for the foreseeable future. There can be no assurance that we will continue to generate cash flows at or above current levels or that we will be able to maintain our ability to borrow under our Credit ~~Facilities.~~Agreements.

Debt

On September 19, 2014, we entered into a Credit and Guaranty Agreement with a group of lenders including Goldman Sachs Bank USA, as administrative agent (the ~~"Credit Agreement"~~“2014 Credit Agreement”). The terms of the 2014 Credit Agreement ~~provide-for~~provided for credit facilities in the aggregate maximum principal amount of $400.0 million, consisting of a senior unsecured term loan facility in the original principal amount of $300.0 million (the ~~"Term~~“2014 Term Loan ~~Facility"~~Facility”) and a senior unsecured revolving credit facility in

the maximum principal amount of $100.0 million (the ~~"Revolving~~“2014 Revolving Credit ~~Facility"~~Facility” and, together with the 2014 Term Loan Facility, the ~~"Credit Facilities"~~“2014 Credit Facilities”).

As of ~~June 30, 2017,~~March 31, 2018, we had outstanding indebtedness under the 2014 Term Loan Facility and capital lease obligations of approximately ~~$251.3~~$225.0 million and approximately ~~$0.3~~$16.9 million, respectively. As of ~~June 30, 2016,~~March 31, 2017, we had outstanding indebtedness under the 2014 Term Loan Facility and capital lease obligations of approximately ~~$273.8~~$258.8 million and approximately ~~$0.4~~$0.3 million, respectively. No amounts were outstanding under the 2014 Revolving Credit Facility as of ~~June 30, 2017~~March 31, 2018 or ~~June 30, 2016.~~March 31, 2017. The 2014 Term Loan Facility ~~has~~had a five-year term and iswas an amortizing facility with quarterly principal payments ~~quarterly~~ and monthly interest ~~payments monthly.~~payments. Scheduled principal payments totaling ~~$15.0~~$11.3 million and scheduled interest payments totaling approximately ~~$2.8~~$1.8 million were paid during the ~~six~~three months ended ~~June 30, 2017.~~March 31, 2018. As of ~~June 30, 2017,~~March 31, 2018, we were in compliance with the covenants under the 2014 Credit Agreement.

On April 2, 2018, we paid in full all existing debt obligations under the 2014 Credit Agreement and terminated all commitments to extend further credit thereunder. On April 2, 2018, we entered into a credit agreement with Morgan Stanley Senior Funding, Inc., as administrative agent. See “Note 8—Subsequent Events” in the Notes to our unaudited condensed consolidated financial statements included under Part I, Item 1 within this Quarterly Report on Form 10-Q for additional information.

Cash Flows

Operating Cash Flow Activities

Cash provided by operating activities during the ~~six~~three months ended ~~June 30, 2017~~March 31, 2018 was approximately ~~$41.1~~$6.9 million, representing an increase in cash inflow of approximately ~~$8.7~~$4.5 million compared with the ~~six~~three months ended ~~June 30, 2016.~~March 31, 2017. Cash provided by operating activities was driven by ~~net income~~improved working capital of approximately ~~$9.1~~$8.0 million ~~as adjusted for~~and the exclusion of non-cash expenses totaling approximately ~~$31.0~~$15.8 million, ~~and~~which was partially offset by net loss of approximately ~~$1.0 million related to the effect of changes in working capital and other balance sheet accounts.~~$16.8 million.

Investing Cash Flow Activities

Cash provided by investing activities during the ~~six~~three months ended ~~June 30, 2017~~March 31, 2018 was approximately ~~$80.7~~$204.5 million compared with approximately ~~$15.5~~$51.0 million during the ~~six~~three months ended ~~June 30, 2016.~~March 31, 2017. Cash provided by investing activities was primarily due to proceeds generated from ~~sales and~~ maturities of available-for-sale securities of approximately ~~$105.2~~$225.2 million, partially offset by approximately ~~$24.6~~$20.8 million of investments in property and equipment and capitalized software.

We make investments in innovation, including research and development expense, capital software development costs, and research and development infrastructure investments, on a recurring basis. We expect our investment in innovation to increase in the foreseeable future to support our continued growth and new service offerings.

Financing Cash Flow Activities

Cash used in financing activities during the ~~six~~three months ended ~~June 30, 2017~~March 31, 2018 was approximately ~~$57.5~~$10.3 million, compared with approximately ~~$2.1~~$33.2 million during the ~~six~~three months ended ~~June 30, 2016.~~March 31, 2017. Cash used in financing activities was primarily due to approximately ~~$45.2 million related to share repurchases and approximately $15.0~~$11.3 million for the repayment of 2014 Credit Facility borrowings.

We have funded and expect to continue to fund repurchases of shares of Class A common stock under our share repurchase program through a combination of cash on hand, cash generated by operations and sales of short-term investments, if needed. During the six months ended June 30, 2017, the Company repurchased an aggregate of 3,697,007 shares of Class A common stock for an aggregate cost of $45.2 million or an average purchase cost of $12.22 per share, excluding commissions. As of June 30, 2017, the Company had repurchased an aggregate of 11,205,992 shares of Class A common stock for approximately $151.4 million or an average cost of $13.51 per share, excluding commissions. As of June 30, 2017, approximately $48.6 million remained available to repurchase shares under the share repurchase program. The share repurchase program does not obligate us to acquire any particular amount of Class A common stock.

Contractual Obligations

During the ~~six~~three months ended ~~June 30, 2017,~~March 31, 2018, there have been no material changes, outside of the ordinary course of business, in our contractual obligations previously disclosed under the caption ~~"Contractual Obligations"~~“Contractual Obligations” in our ~~2016~~2017 Form 10-K.

Off-Balance Sheet Arrangements

As of ~~June 30, 2017,~~March 31, 2018, we did not have any off-balance sheet arrangements.

Recently Issued Accounting Standards

Recently issued accounting standards and their expected impact, if any, are discussed in Note 1, ~~"Basis~~“Basis of ~~Presentation"~~Presentation”, in the notes to our unaudited condensed consolidated financial statements, included under Item 1 within this Quarterly Report on Form 10-Q and in Note 2, ~~"Summary~~“Summary of Significant Accounting Policies,"” in the notes to our consolidated financial statements, included under Item 15 within our ~~2016~~2017 Form 10-K.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Variable Rate Debt Risk. Our variable rate debt includes our 2014 Term Loan Facility and our 2014 Revolving Credit Facility. As of ~~June 30, 2017,~~March 31, 2018, we had ~~$251.3~~$225.0 million outstanding under our 2014 Term Loan Facility at an effective interest rate of approximately ~~2.2%~~2.9%. As a result, if market interest rates were to increase by 1.0%, or 100 basis points, interest expense would decrease future earnings and cash flows, net of estimated tax benefits, by approximately ~~$1.5~~$1.6 million annually, assuming that we do not enter into contractual hedging arrangements. As of ~~June 30, 2017,~~March 31, 2018, there was no balance outstanding on the 2014 Revolving Credit Facility.

Marketable Securities Risk. We had short-term investment portfolios, including cash held in money market funds, totaling approximately ~~$401.2~~$40.4 million as of ~~June 30, 2017.~~March 31, 2018. This amount was invested primarily in marketable securities including corporate notes and bonds, U.S. agency obligations, ~~U.S. treasury securities~~ and money market funds. Our investments are made for capital preservation purposes. We do not enter into investments for trading or speculative purposes.

Our short-term investments are subject to market risk due to changes in interest rates, which could affect our results of operations. ~~Fixed rate securities may have their market value adversely affected due to a~~A rise in interest rates may adversely affect the market value of fixed rate securities, while floating rate securities may produce less income than expected if interest rates fall. Due in part to these factors, our future investment income may fluctuate due to changes in interest rates or we may suffer losses in principal if we are forced to sell securities that decline in market value due to changes in interest rates. However because we classify our marketable securities as ~~"available-for-sale,"~~“available-for-sale,” no gains or losses are recognized due to changes in interest rates unless such securities are sold prior to maturity or declines in fair value are determined to be other-than-temporary.

An immediate increase of 100-basis points in interest rates would have ~~resulted in an approximate $2.5 million~~no material impact on the market value ~~reduction in~~of our investment portfolio as of ~~June 30, 2017.~~March 31, 2018. An immediate decrease of 100-basis points in interest rates would have increased the market value of our investment portfolio by approximately ~~$2.5~~$0.3 million as of ~~June 30, 2017.~~March 31, 2018. This estimate is based on a sensitivity model that measures market value changes when changes in interest rates occur. Fluctuations in the value of our investment securities caused by a change in interest rates (gains or losses on the carrying value) are recorded in accumulated other comprehensive income (loss), and are realized only if we sell the underlying securities prior to their maturity.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer ~~("CEO"~~(“CEO”) and chief financial officer ~~("CFO"~~(“CFO”), has evaluated the effectiveness of our disclosure controls and procedures, (as defined in Rules 13a- 15(e) and 15d- 15(e) under the Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our CEO and CFO have concluded that, as of ~~June 30, 2017,~~March 31, 2018, our disclosure controls and procedures were designed at a reasonable assurance level to ensure that material information relating to Inovalon Holdings, Inc., including its consolidated subsidiaries, is made known to our CEO and CFO by others within those entities, particularly during the period in which this report was being prepared and that our disclosure controls and procedures were effective in providing reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control

There have been no changes in the ~~Company's~~Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the ~~six~~three months ended ~~June 30, 2017~~March 31, 2018 that have materially affected, or are reasonably likely to materially affect, the ~~Company's~~Company’s internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

See ~~"Note 5—~~“Note 6—Commitments and ~~Contingencies"~~Contingencies” in the Notes to our unaudited condensed consolidated financial statements included under Part I, Item 1 within this Quarterly Report on Form 10-Q.

Item 1A. Risk Factors

For a discussion of potential risks and uncertainties related to our Company see the information in Part I, Item 1A ("(“Risk ~~Factors"~~Factors”) of our ~~2016~~2017 Form 10-K for the year ended December 31, ~~2016.~~2017. There have been no material changes to the risk factors previously disclosed in our ~~2016~~2017 Form ~~10-K.~~10-K, other than the addition of the following two new risk factors:

Our debt may restrict our future operations.

We have substantial debt and have the ability to incur additional debt. As of May 8, 2018, we had approximately $980.0 million of outstanding principal indebtedness. Our incurrence of substantial amounts of debt may have significant consequences. For instance, it could:

make it more difficult for us to satisfy our financial obligations, including those relating to our outstanding debt;

require us to dedicate a substantial portion of our cash flow from operations to the payment of interest and principal due under our debt, which will reduce funds available for other business purposes;

increase our vulnerability to general adverse economic and industry conditions;

limit our flexibility in planning for, or reacting to, changes in our business;

place us at a competitive disadvantage compared with some of our competitors that have less debt; and

limit our ability to obtain additional financing required to fund working capital and capital expenditures and for other general corporate purposes.

Our 2018 Credit Agreement and the terms of our other debt instruments, including agreements relating to debt we may incur in the future, contain or will contain covenants imposing significant restrictions on our business. These restrictions may affect our ability to operate our business and may limit our ability to take advantage of potential business opportunities as they arise. For instance, these covenants place restrictions on our ability to, among other things: incur additional debt; create additional liens, merge or consolidate; make certain investments, loans, advances, guarantees and acquisitions; make certain restricted payments; or enter into transactions with affiliates. In addition, our 2018 Credit Agreement requires that we comply with certain financial ratios, including a maximum senior secured net leverage ratio test. Our ability to comply with these covenants may be adversely affected by events beyond our control, including prevailing economic, financial and industry conditions. A breach, or alleged breach, of any of these covenants could result in a default and our lenders could elect to declare all amounts outstanding to be immediately due and payable and to terminate all commitments to extend further credit. If we were unable to repay those amounts, the secured lenders could proceed against the collateral granted to them to secure such indebtedness. There can be no assurance that we will have sufficient assets to repay amounts due under our indebtedness.

Our failure to hedge effectively against interest rate changes may adversely affect results of operations.

Our 2018 Term Facility currently bears interest at variable rates and we may incur additional variable rate debt in the future. Accordingly, increases in interest rates on variable rate debt would increase our interest expense, which could reduce net earnings and cash available for payment of our debt obligations. We currently manage our exposure to interest rate volatility by using interest rate swap agreements and may in the future use additional interest rate hedging arrangements, such as interest cap agreements. These agreements involve risks, such as the risk that counterparties may fail to honor their obligations under these arrangements, that these arrangements may not be effective in reducing our exposure to interest rate increases and that a court could rule that such an agreement is not legally enforceable. In addition, hedging strategies involve transaction and other costs, and our hedging strategies and the derivatives that we use may not completely offset the risks of interest rate volatility and may result in or magnify losses. Furthermore, interest rate derivatives may not be available at all, or at favorable terms, particularly during economic downturns. Failure to hedge effectively against interest rate changes may materially and adversely affect our results of operations.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Unregistered Sales of Equity Securities

None.

Use of Proceeds from Registered Securities

On February 18, 2015, we completed our initial public offering ~~("IPO"~~(“IPO”) of 22,222,222 shares of Class A common stock and, upon the ~~underwriters'~~underwriters’ exercise of their option to purchase additional shares, issued an additional 3,142,581 shares of Class A common stock for a total of 25,364,803 shares issued. All of the shares issued in the IPO were primary shares offered by us as none of our stockholders sold any shares in the IPO. The offering price of the shares sold in the IPO was $27.00 per share, resulting in net proceeds to us, after underwriters' discounts and commissions and other expenses payable by us, of $639.1 million. All of the shares were sold pursuant to our registration statement on Form S-1, as amended (File No. 333-201321), that was declared effective by the SEC on February 11, 2015. ~~Goldman, Sachs & Co., Morgan Stanley & Co. LLC, and Citigroup Global Markets Inc. acted as joint book-running managers for the IPO and as representatives of the underwriters.~~ The principal purposes of our IPO were to create a public market for our Class A common stock and thereby enable future access to the public equity markets by us and our stockholders, and obtain additional capital. On September 1, 2015, we used approximately $126.2 million of the net proceeds from the IPO to complete the acquisition of Avalere Health, Inc. On October 1, 2016, we committed $120.0 million as partial consideration for our acquisition of Creehan. Through ~~June 30,~~December 31, 2017, in aggregate, we ~~have~~ used ~~approximately $151.4~~$200.0 million of the net proceeds from the IPO to repurchase outstanding Class A common shares under our share repurchase program. We ~~intend to use~~used the remaining net proceeds to us from our IPO for working capital and other general corporate purposes; other than funding the share repurchase program, we do not currently have any specific uses of the remaining net proceeds. Additionally, we may useto fund a portion of the ~~remaining net proceeds for additional acquisitions of complementary businesses, technologies, or other assets, or~~cash used to ~~repay outstanding indebtedness.~~acquire ABILITY on April 2, 2018.

Purchases of Equity Securities by the Issuer or Affiliated Purchasers

~~The following table presents a summary of share repurchases made by the Company during the quarter ended June 30, 2017:~~

Period Total Number of
Shares
Purchased Average Price
Paid per Share Total Number of Shares
Purchased as Part of
Publicly Announced Plans
or Programs Maximum Number of Shares (or
approximate dollar value) that May
Yet be Purchased under the Plans or
Programs(1)
April 739,246
$ 12.16
739,246
$ 59,394,911
May 493,238
13.26
493,238
52,852,233
June 323,122
13.17
323,122
48,596,387
Total 1,555,606
$ 12.72
1,555,606
$ 48,596,387

~~(1)~~

On May 4, 2016, we announced that our Board of Directors authorized a program to repurchase up to $100 million of Inovalon's Class A common stock through December 31, 2016. On November 2, 2016, we announced that our Board of Directors authorized an expansion of the share repurchase program to repurchase up to an additional $100 million of shares of Inovalon's Class A common stock (bringing the total to $200 million) through December 31, 2017. As of June 30, 2017, the Company had repurchased 11,205,992 shares at an average purchase price of $13.51 per share for a total purchase price

of approximately $151.4 million under this program. The Company intends to use a combination of cash on hand, cash generated by operations and sales of short-term investments to fund additional repurchases under this program through open market or privately negotiated transactions.None.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

EXHIBIT ~~INDEX~~INDEX



Exhibit Number		Description of Document
2.1		Agreement and Plan of Merger by and among Inovalon Holdings, Inc., New Heights Merger Corporation, Butler Group Holdings, Inc. and Shareholder Representative Services LLC, dated March 6, 2018. (Incorporated by reference from Exhibit 2.1 to the Current Report on Form 8-K filed March 7, 2018)

10.1	*	Debt Commitment Letter with Morgan Stanley Senior Funding, Inc., dated March 6, 2018. (Incorporated by reference from Exhibit 10.1 to the Current Report on Form ~~of Non-Employee Director's Restricted Stock Unit Deferral Election Form.~~8-K filed March 7, 2018)

10.2	*	~~Form of Restricted Stock Unit Award under the 2015 Omnibus Incentive Plan (Non-Employee Directors).~~

~~10.3~~	*	~~Executive Separation~~ Agreement ~~and Release,~~for Consulting Services with Mark A. Pulido, dated ~~April 27, 2017, by and between Inovalon Holdings, Inc. and Joseph R. Rostock.~~March 29, 2018.

31.1	*	Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2	*	Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1	**	Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2	**	Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS	*	XBRL Instance Document

101.SCH	*	XBRL Taxonomy Extension Schema

101.CAL	*	XBRL Taxonomy Extension Calculation Linkbase

101.DEF	*	XBRL Taxonomy Extension Definition Linkbase

101.LAB	*	XBRL Taxonomy Extension Label Linkbase

101.PRE	*	XBRL Taxonomy Extension Presentation Linkbase


*	Filed herewith.


**	This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (Securities Act), or the Exchange Act.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.




Date: ~~August 3, 2017~~May 8, 2018	INOVALON HOLDINGS, INC.
	By:	/s/ KEITH R. DUNLEAVY, M.D.
		Keith R. Dunleavy, M.D. Chief Executive Officer & Chairman (Principal Executive Officer)

	By:	/s/ ~~CHRISTOPHER E. GREINER~~JONATHAN R. BOLDT
		~~Christopher E. Greiner~~Jonathan R. Boldt Interim Chief Financial ~~& Operating~~ Officer (Principal Financial Officer)



Share Purchase Agreement purchase price	$	130,000
Working capital adjustment	755
Subtotal	130,755
Fair value adjustments:
Marketability restrictions on equity consideration	(2,236		)
Contingent consideration probability of achievement adjustment.	(12,400		)
Post-acquisition compensation expense	(5,952		)
Total fair value purchase price	$	110,167



Cash	$	89,370
Issuance of Class A common stock	7,764
Working capital adjustment payable	433
Contingent consideration	12,600
Total fair value purchase price	$	110,167



	Preliminary Recorded Value
Cash and cash equivalents	$	861
Accounts receivable	9,048
Other current assets	171
Property, equipment and capitalized software	641
Intangible assets(1)	50,900
Goodwill(2)	51,989
Total assets acquired	113,610
Current liabilities	(1,007		)
Deferred revenue	(2,436		)
Total liabilities assumed	(3,443		)
Net assets acquired	$	110,167



	Weighted Average Useful Life	Recorded Value
Customer relationships	8 years	$	36,500
Tradename	4 years	4,000
Technology	4 years	8,800
In-process Research and Development	indefinite	1,600
Total intangible assets		$	50,900



Goodwill as of January 1, 2017	$	184,557
Measurement period adjustments	1,002
Goodwill as of June 30, 2017	$	185,559



Period	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number of Shares (or approximate dollar value) that May Yet be Purchased under the Plans or Programs(1)
April	739,246	$	12.16	739,246	$	59,394,911
May	493,238	13.26		493,238	52,852,233
June	323,122	13.17		323,122	48,596,387
Total	1,555,606	$	12.72	1,555,606	$	48,596,387